US20050043244A1 - Water-soluble SHPs as novel alkylating agents - Google Patents
Water-soluble SHPs as novel alkylating agents Download PDFInfo
- Publication number
- US20050043244A1 US20050043244A1 US10/950,890 US95089004A US2005043244A1 US 20050043244 A1 US20050043244 A1 US 20050043244A1 US 95089004 A US95089004 A US 95089004A US 2005043244 A1 US2005043244 A1 US 2005043244A1
- Authority
- US
- United States
- Prior art keywords
- composition according
- pharmaceutically acceptable
- acceptable salt
- glu
- glutamyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940100198 alkylating agent Drugs 0.000 title description 4
- 239000002168 alkylating agent Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 126
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 30
- -1 OPO3H2 Chemical group 0.000 claims abstract description 24
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims abstract description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 9
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims abstract description 8
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 5
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 53
- 201000011510 cancer Diseases 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 21
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 108010020346 Polyglutamic Acid Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000000337 alpha-glutamyl group Chemical group 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 229940009456 adriamycin Drugs 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960004679 doxorubicin Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 etoposide Drugs 0.000 claims description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 3
- 229960005277 gemcitabine Drugs 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
- 229960004528 vincristine Drugs 0.000 claims description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 26
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract description 22
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 19
- 239000002253 acid Substances 0.000 abstract description 18
- 239000004220 glutamic acid Substances 0.000 abstract description 14
- 235000013922 glutamic acid Nutrition 0.000 abstract description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract description 9
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 82
- 239000000243 solution Substances 0.000 description 48
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- PVCULFYROUOVGJ-UHFFFAOYSA-N 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea Chemical compound CNC(=O)N(S(C)(=O)=O)N(S(C)(=O)=O)CCCl PVCULFYROUOVGJ-UHFFFAOYSA-N 0.000 description 38
- 229940002612 prodrug Drugs 0.000 description 29
- 239000000651 prodrug Substances 0.000 description 29
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 24
- 238000011282 treatment Methods 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000004679 31P NMR spectroscopy Methods 0.000 description 17
- QVKFHBWVOPWLGX-UHFFFAOYSA-N n'-(2-chloroethyl)-n'-methylsulfonylmethanesulfonohydrazide Chemical compound CS(=O)(=O)NN(S(C)(=O)=O)CCCl QVKFHBWVOPWLGX-UHFFFAOYSA-N 0.000 description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 229910019142 PO4 Inorganic materials 0.000 description 13
- 230000000259 anti-tumor effect Effects 0.000 description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 13
- 235000021317 phosphate Nutrition 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 239000010452 phosphate Substances 0.000 description 11
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000007062 hydrolysis Effects 0.000 description 10
- 238000006460 hydrolysis reaction Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 9
- 230000009826 neoplastic cell growth Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000002252 carbamoylating effect Effects 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical class CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 108010080937 Carboxypeptidases A Proteins 0.000 description 6
- 102000000496 Carboxypeptidases A Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 238000001994 activation Methods 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 230000002349 favourable effect Effects 0.000 description 6
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 6
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 0 *N(Cc1c([2*])c([3*])c([4*])c([5*])c1[6*])C(=O)N(SOOC)N(*)SOOC Chemical compound *N(Cc1c([2*])c([3*])c([4*])c([5*])c1[6*])C(=O)N(SOOC)N(*)SOOC 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 102000004459 Nitroreductase Human genes 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000002152 alkylating effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 201000005296 lung carcinoma Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 108020001162 nitroreductase Proteins 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000006268 reductive amination reaction Methods 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 description 4
- NUKKYWBTRJJXQF-UHFFFAOYSA-N 1-amino-1-benzyl-3-methylurea Chemical compound CNC(=O)N(N)CC1=CC=CC=C1 NUKKYWBTRJJXQF-UHFFFAOYSA-N 0.000 description 4
- RZVJTHXDHLQJIK-UHFFFAOYSA-N 4,5-dichloro-2-hydroxybenzaldehyde Chemical compound OC1=CC(Cl)=C(Cl)C=C1C=O RZVJTHXDHLQJIK-UHFFFAOYSA-N 0.000 description 4
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000019445 benzyl alcohol Nutrition 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 230000030609 dephosphorylation Effects 0.000 description 4
- 238000006209 dephosphorylation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- NTUGPDFKMVHCCJ-UHFFFAOYSA-N ditert-butyl 2-aminopentanedioate Chemical compound CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C NTUGPDFKMVHCCJ-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010504 bond cleavage reaction Methods 0.000 description 3
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 3
- 230000022244 formylation Effects 0.000 description 3
- 238000006170 formylation reaction Methods 0.000 description 3
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 3
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000003656 tris buffered saline Substances 0.000 description 3
- YGSRAYJBEREVRB-VIFPVBQESA-N (2s)-5-[(2-methylpropan-2-yl)oxy]-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)CC[C@@H](C(O)=O)NC(=O)OC(C)(C)C YGSRAYJBEREVRB-VIFPVBQESA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- MYRBSVRXUYEZPM-UHFFFAOYSA-N 2,3-dichloro-6-hydroxybenzaldehyde Chemical compound OC1=CC=C(Cl)C(Cl)=C1C=O MYRBSVRXUYEZPM-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical class CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- BXQPCQLNANMZFL-UHFFFAOYSA-N 2-hydroxy-5-(trifluoromethyl)benzaldehyde Chemical compound OC1=CC=C(C(F)(F)F)C=C1C=O BXQPCQLNANMZFL-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- LWXFCZXRFBUOOR-UHFFFAOYSA-N 4-chloro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1O LWXFCZXRFBUOOR-UHFFFAOYSA-N 0.000 description 2
- 102000002226 Alkyl and Aryl Transferases Human genes 0.000 description 2
- 108010014722 Alkyl and Aryl Transferases Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 150000003938 benzyl alcohols Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000005341 metaphosphate group Chemical group 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- BVJSUAQZOZWCKN-UHFFFAOYSA-N p-hydroxybenzyl alcohol Chemical compound OCC1=CC=C(O)C=C1 BVJSUAQZOZWCKN-UHFFFAOYSA-N 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000004060 quinone imines Chemical class 0.000 description 2
- 238000009790 rate-determining step (RDS) Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 2
- 150000003870 salicylic acids Chemical class 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- AXKGIPZJYUNAIW-UHFFFAOYSA-N (4-aminophenyl)methanol Chemical compound NC1=CC=C(CO)C=C1 AXKGIPZJYUNAIW-UHFFFAOYSA-N 0.000 description 1
- ISNKSXRJJVWFIL-UHFFFAOYSA-N (sulfonylamino)amine Chemical class NN=S(=O)=O ISNKSXRJJVWFIL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- SZCBDIVMCGFVPW-UHFFFAOYSA-N 1-[4-(aminomethyl)-2,6-di(propan-2-yl)phenyl]-3-[1-butyl-4-(3-methoxyphenyl)-2-oxo-1,8-naphthyridin-3-yl]urea;hydrochloride Chemical compound Cl.CC(C)C=1C=C(CN)C=C(C(C)C)C=1NC(=O)NC=1C(=O)N(CCCC)C2=NC=CC=C2C=1C1=CC=CC(OC)=C1 SZCBDIVMCGFVPW-UHFFFAOYSA-N 0.000 description 1
- GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
- CMWKITSNTDAEDT-UHFFFAOYSA-N 2-nitrobenzaldehyde Chemical class [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
- WDNBURPWRNALGP-UHFFFAOYSA-N 3,4-Dichlorophenol Chemical compound OC1=CC=C(Cl)C(Cl)=C1 WDNBURPWRNALGP-UHFFFAOYSA-N 0.000 description 1
- BAYGVMXZJBFEMB-UHFFFAOYSA-N 4-(trifluoromethyl)phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1 BAYGVMXZJBFEMB-UHFFFAOYSA-N 0.000 description 1
- NEPPSDXLISKMNU-UHFFFAOYSA-N 5-chloro-2-(hydroxymethyl)phenol Chemical compound OCC1=CC=C(Cl)C=C1O NEPPSDXLISKMNU-UHFFFAOYSA-N 0.000 description 1
- FUGKCSRLAQKUHG-UHFFFAOYSA-N 5-chloro-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Cl)C=C1C=O FUGKCSRLAQKUHG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical class NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- JUQRWCMITUNYSA-UHFFFAOYSA-N O=S(=O)=NN=S(=O)=O Chemical class O=S(=O)=NN=S(=O)=O JUQRWCMITUNYSA-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- MMHBAYBLHOGWMN-UHFFFAOYSA-N [2-[[[[2-chloroethyl(methylsulfonyl)amino]-methylsulfonylcarbamoyl]-methylamino]methyl]phenyl] diethyl phosphate Chemical compound CCOP(=O)(OCC)OC1=CC=CC=C1CN(C)C(=O)N(N(CCCl)S(C)(=O)=O)S(C)(=O)=O MMHBAYBLHOGWMN-UHFFFAOYSA-N 0.000 description 1
- ZXTRLHCCUZCFAW-UHFFFAOYSA-N [2-[[[[2-chloroethyl(methylsulfonyl)amino]-methylsulfonylcarbamoyl]-methylamino]methyl]phenyl] dihydrogen phosphate Chemical compound ClCCN(S(C)(=O)=O)N(S(C)(=O)=O)C(=O)N(C)CC1=CC=CC=C1OP(O)(O)=O ZXTRLHCCUZCFAW-UHFFFAOYSA-N 0.000 description 1
- DJVJIPDZYKIMPL-UHFFFAOYSA-N [4-[[[[2-chloroethyl(methylsulfonyl)amino]-methylsulfonylcarbamoyl]-methylamino]methyl]phenyl] dihydrogen phosphate Chemical compound ClCCN(S(C)(=O)=O)N(S(C)(=O)=O)C(=O)N(C)CC1=CC=C(OP(O)(O)=O)C=C1 DJVJIPDZYKIMPL-UHFFFAOYSA-N 0.000 description 1
- RYQDCINEYRCYTC-UHFFFAOYSA-N [H]N(C)C(=O)N(SOOC)N(CCCl)SOOC Chemical compound [H]N(C)C(=O)N(SOOC)N(CCCl)SOOC RYQDCINEYRCYTC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- RAFKCLFWELPONH-UHFFFAOYSA-N acetonitrile;dichloromethane Chemical compound CC#N.ClCCl RAFKCLFWELPONH-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004638 bioanalytical method Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 101150093134 cnu gene Proteins 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000003970 colon lymphoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BPFNBRGFKGSFJI-UHFFFAOYSA-L disodium [2-[[[[2-chloroethyl(methylsulfonyl)amino]-methylsulfonylcarbamoyl]-methylamino]methyl]phenyl] phosphate Chemical compound [Na+].[Na+].CN(Cc1ccccc1OP([O-])([O-])=O)C(=O)N(N(CCCl)S(C)(=O)=O)S(C)(=O)=O BPFNBRGFKGSFJI-UHFFFAOYSA-L 0.000 description 1
- MWXRALBRZBHXSR-UHFFFAOYSA-L disodium [4-chloro-2-[[[[2-chloroethyl(methylsulfonyl)amino]-methylsulfonylcarbamoyl]-methylamino]methyl]phenyl] phosphate Chemical compound [Na+].[Na+].CS(=O)(=O)N(N(CCCl)S(=O)(=O)C)C(=O)N(C)CC1=C(C=CC(=C1)Cl)OP([O-])([O-])=O MWXRALBRZBHXSR-UHFFFAOYSA-L 0.000 description 1
- DILFAWGFXISZSY-UHFFFAOYSA-L disodium [5-chloro-2-[[[[2-chloroethyl(methylsulfonyl)amino]-methylsulfonylcarbamoyl]-methylamino]methyl]phenyl] phosphate Chemical compound [Na+].[Na+].CS(=O)(=O)N(N(CCCl)S(=O)(=O)C)C(=O)N(C)CC1=C(C=C(C=C1)Cl)OP([O-])([O-])=O DILFAWGFXISZSY-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- QLXMFOMGVYGWAC-INIZCTEOSA-N ditert-butyl (2s)-2-[(4-formylphenoxy)carbonylamino]pentanedioate Chemical compound CC(C)(C)OC(=O)CC[C@@H](C(=O)OC(C)(C)C)NC(=O)OC1=CC=C(C=O)C=C1 QLXMFOMGVYGWAC-INIZCTEOSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002642 gamma-glutamyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000006204 intramuscular dosage form Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- JHHMSRLTZAUMOJ-UHFFFAOYSA-N methanamine;oxolane Chemical compound NC.C1CCOC1 JHHMSRLTZAUMOJ-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 101150118830 ydgT gene Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/52—Y being a hetero atom
- C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
- C07C311/55—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
Definitions
- the present invention relates to metabolically activated sulfonyl hydrazine prodrugs (SHPs) exhibiting anti-tumor activity in mammals.
- SHPs metabolically activated sulfonyl hydrazine prodrugs
- Alkylating agents are among the most effective therapeutic agents currently available to treat different malignancies, and are widely used in the clinic (Katzung, In Basic & Clinical Pharmacology, 7th edition, 1998, Appleton & Lange, Stamford, 881). The high degree of cytotoxicity is attributed to the ability to induce DNA interstrand cross-linking thereby inhibiting replication (Rajski and Williams, Chem Reviews 1998, 98: 2723).
- the alkylating agents the CNU (chloroethylnitrosourea) series have been widely used clinically to treat brain tumors, colon cancer and lymphomas (DeVita, et al. Cancer Res. 1965, 25: 1876; and Nissen, et al.
- SHPs 1,2-bis(sulfonyl)hydrazine prodrugs
- the antitumor activity has been suggested to result from chloroethylating and subsequent cross-linking of DNA (Kohn, In Recent Results in Cancer Research , Eds. Carter, et al., 1981, Springer, Berlin, vol. 76: 141; and Shealy, et al., J Med Chem. 1984, 27: 664).
- the carbamoylating species i.e., the isocyanate
- the carbamoylating species i.e., the isocyanate
- hydroxyethylation of DNA is a carcinogenic and/or mutagenic event (Swenson, et
- VNP40101M 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine
- the current lead compound in the SHP series has lower toxicity to hosts and better anti-tumor activities against the L1210 murine leukemia, L1210/BCNU, L1210/CTX, L1210/MEL (1,3-bis(2-chloroethyl)-1-nitrosourea, cyclophosphamide and melphalan resistant sublines), P388 leukemia, M109 lung carcinoma, B16 melanoma, C26 colon carcinoma and U251 glioma than chloroethylnitrosourea (CNU) derivatives and other SHP analogs (Shyam, et al.
- VNP4011M is effective in crossing the blood brain barrier (BBB) and eradicating leukemia cells implanted intracranially (>6.54 log cell kill), rivaling the efficacy of BCNU (Finch, et al. Cancer Biochem Biophys. 2001, 61: 3033).
- FIG. 1 a relatively specific O 6 -guanine chloroethylator, producing minimal alkylation of the N 7 -position of guanine (Penketh, et al. J Med Chem. 1994, 37: 2912; and Penketh, et al. Biochem Pharmacol. 2000, 59: 283).
- Methyl isocyanate released from VNP40101M has the ability to inhibit various DNA repair enzymes including O 6 -alkylguanine-DNA alkyltransferase leading to stabilization of the O 6 -alkylguanine monoalkyl species in DNA, which leads to a larger percentage of interstrand cross-links (Baril, et al. Cancer Res. 1975, 35: 1).
- VNP40101M is currently in clinical trials in patients with solid tumors and hematologic malignancies. VNP40101M is not very soluble in aqueous solution; polyethylene glycol (PEG) and ethanol are included in the vehicle of the finished product to promote solubility. Both PEG and ethanol are acceptable vehicles for human use but may cause side effects such as hemolysis and phlebitis at high concentrations, as indicated in animal studies. VNP40101M is very well tolerated in humans and could be given at higher 110 doses, and could in theory produce a higher degree of efficacy, if PEG and ethanol could be eliminated from the vehicle.
- PEG polyethylene glycol
- our aim was to synthesize a series of SHPs that (a) were capable of improving its water-solubility and stability in aqueous solution at pH 3 to 9; (b) were capable of forming chloroethylating species; (c) were devoid of hydroxyethylating activity; (d) were capable of forming methyl isocyanate; and (e) were capable of improving pharmacokinetic profiles (e.g., longer half-life in vivo).
- Compounds I may be considered as prodrugs of VNP40101M that has been identified as an alkylating agent against a broad anticancer spectrum of neoplastic disease states, including, for example, numerous solid tumors. Thus, compounds I may generate the same active species as VNP40101M.
- FIGS. 3 and 4 Further examples of bioactivated prodrugs are shown in FIGS. 3 and 4 .
- the nitro analogs shown in FIG. 3 are examples of compounds that would be both water soluble and selectively activated under conditions of hypoxia. Release of VNP40101M would only occur on reduction of the nitro group under conditions of hypoxia. Compounds II would be reduced by nitroreductase (NR) to the corresponding amino analogs, which would be subsequently fragmented into VNP40101M and a quinone-imine methide.
- NR nitroreductase
- Coli or Bacillus spp. is widely used in ADEPT (antibody-directed enzyme prodrug therapy) or GDEPT (gene-directed enzyme prodrug therapy) for cancer therapy (Anlezark, et al. WO93/08288, 1993).
- FIG. 4 illustrates the use of peptidases to generate VNP40101M intratumorally.
- carboxypeptidases such as carboxypeptidase G2 (CPG2) and carboxypeptidase A (CPA) has been shown previously.
- CPG2 an enzyme isolated from Pseudomonas , is capable of removing glutamate residues from folates and methotrexate. It has been employed in the ADEPT or GDEPT system to activate prodrugs containing glutamate residues (Bagshawe, et al. WO88/07378, 1988; Springer, et al.
- Compounds III and Compounds IV would be cleaved by the corresponding CPG2 or CPA, which may either be introduced as an antibody conjugate or a transgene (Pawelek, et al. U.S. Pat. No. 6,190,657, 2001), to form VNP40101M and a quinone methide or quinone-imine methide.
- an object of the present invention is to provide compounds, pharmaceutical compositions and methods for the treatments of neoplasia, including animal and human cancer.
- an object of the present invention is to provide methods of treating neoplasia utilizing compositions that exhibit favorable and enhanced characteristics of activity, pharmacokinetics, bioavailability and reduced toxicity.
- the present invention relates to compounds or their pharmaceutically acceptable salts according to the structure (I):
- preferred agents in the class of Compounds I are ortho-phosphate-bearing series where R is —CH 2 CH 2 Cl; R′ is —CH 3 ; R 2 is a phosphate group which can be the free acid or its pharmaceutically acceptable salt (preferably Na).
- R 4 is Cl, F or Br (preferably Cl) when R 3 , R 5 and R 6 are H.
- R 5 is Cl, F or Br (preferably Cl, F) when R 3 , R 4 and R 6 are H.
- R 3 , R 4 , R 5 and R 6 are selected from F, Cl, Br or I (preferably, both substituents are the same and more preferably, both substituents are Cl), the other two of R 3 , R 4 , R 5 and R 6 are H.
- Preferred agents in the class of Compounds II are meta-phosphate-bearing nitro-containing analogs of SHPs.
- the phosphate group can be the free acid or its pharmaceutically acceptable salt (preferably Na).
- R 2 is NO 2 when R 4 is H.
- R 4 is NO 2 when R 2 is H.
- Preferred agents in the classes of Compounds III and IV are glutamyl residue-conjugated analogs of SHPs.
- the acid-terminal can be the free acid or its pharmaceutically acceptable salt (preferably, Na).
- R 7 can be H or a polyglutamic acid polypeptide residue.
- Compounds according to the present invention and especially the preferred compositions according to the present invention, as set forth above, are extremely effective compounds for the treatment of neoplasia. They also exhibit at least one or more improvements such as an enhanced anti-neoplasia activity, a reduced toxicity, a higher water-solubility, or a more favorable pharmacokinetic profile compared to VNP40101M. Thus, preferred compounds according to the present invention could have a higher therapeutic index (i.e., a better benefit/risk ratio), than VNP40101M.
- Compounds according to the present invention may be used in pharmaceutical compositions for the treatment of cancer, as well as a number of other conditions and/or disease states. Examples according to the present invention may be as intermediates in the synthesis of other compounds exhibiting biological activity as well as standards for determining the biological activity of the present compounds. In some applications, the present compounds may be used for treating microbial infections, especially including viral, bacterial, and fungal infections. These compounds comprise an effective amount of any one or more of the compounds disclosed hereinabove, optionally in combination with a pharmaceutically acceptable additive, carrier, or excipient.
- a further aspect of the present invention relates to the treatment of cancer, comprising administering to a patient in need thereof an effective amount of a compound as described hereinabove, optionally in combination with a pharmaceutically acceptable additive, carrier, or excipient.
- the present invention also relates to methods for treating neoplasia in mammals comprising administering an effective amount of a compound as described hereinabove to a patient suffering from cancer.
- the treatment of solid malignant tumors, leukemia, and lymphomas comprising administering to a patient an anti-tumor effective amount of one or more these agents is a preferred embodiment of the present invention.
- the treatment of various other related disease states may also be effected using the compounds of the present invention. This method may also be used in comparison tests such as assays for determining the activities of related analogs as well as for determining the susceptibility of a patient's cancer to one or more of the compounds according to the present invention.
- FIG. 1 is a pictorial representation of a suggested mechanism of activation of VNP40101M.
- FIGS. 2, 3 and 4 are pictorial representations of the certain chemical embodiments and their proposed mechanisms of activation according to the present invention.
- FIGS. 5-9 are pictorial representations of chemical schemes for synthesizing compounds according to the present invention.
- FIGS. 10-15 are pictorial representations of experimental results which are presented in the present application related to the efficacy and toxicity of certain preferred embodiments according to the present invention.
- patient is used throughout the specification to describe an animal, including a mammal and preferably a human, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.
- treatment including prophylactic treatment
- patient refers to that specific animal.
- patients are human patients.
- an effective amount is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which may be used to produce an intended result within its use in context, generally, a favorable change in the disease or condition treated, whether that change is a remission, a decrease in growth or size of cancer or a tumor, a favorable physiological result, a reduction in the growth or elaboration of a tumor, cancerous tissue, or the like, depending upon the disease or condition treated.
- Neoplasia is used throughout the specification to describe the pathological process that results in the formation and growth of a neoplasm, i.e., an abnormal tissue that grows by cellular proliferation more rapidly than normal tissue and continues to grow after the stimuli that initiated the new growth cease.
- Neoplasia could be a distinct mass of tissue that may be benign (benign tumor) or malignant (carcinoma).
- the term neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic, and solid tumors.
- cancer and the term “tumor” used in this application is interchangeable with the term “neoplasia”.
- Cancer which may be treated using compositions according to the present invention include, for example, stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, melanoma, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' Tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney, lymphoma, among others.
- the treatment of tumors comprising administering to a patient an anti-tumor effective amount of one or more these agents is a preferred embodiment of the present invention.
- alkyl is used throughout the specification to describe a fully saturated hydrocarbon radical containing between one to seven carbon units.
- Alkyl groups for use in the present invention include linear, branched-chain or cyclic groups, such as preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, cyclohexyl, methylcyclopropyl and methylcyclohexyl.
- salt is used throughout the specification to describe any salt consistent with the use of the compounds according to the present invention.
- salt shall mean a pharmaceutically acceptable salt, consistent with the use of the compounds as pharmaceutical agents.
- glu or (“Glu) used in chemical formulas according to the present invention refers to a glutamic acid residue or derivative within context which may be bonded on its amino group with another carboxyl group (e.g., RCOOH) or on one of its carboxyl groups with a hydroxyl group or an amino group.
- Glutamic acid HOOCCH(NH 2 )CH 2 CH 2 COOH
- glutamic acid may be bonded on one of the two carboxyl groups with another amino group (RNH 2 ) or a hydroxyl group (ROH) to form the corresponding ⁇ -glutamyl or ⁇ -glutamyl amide or ester compound.
- RNH 2 another amino group
- ROH a hydroxyl group
- glutamate may be bonded on its amino group with a carboxyl group forming an N-glutamyl amide derivative.
- a single glutamyl residue may be present, as well as a polyglutamyl polypeptide residue, which is a polypeptide formed from two or more glutamate amino acids.
- OCO(Glu) is representative of glutamyl residue ( ⁇ - or ⁇ -) which is bonded to a free hydroxyl group to form the ester with the ⁇ - or ⁇ -carboxylic group (preferably, the ⁇ carboxylic acid group of glutamic acid).
- NHCO(Glu) is representative of a glutamyl residue ( ⁇ - or ⁇ -) which is bonded to a free amine group to form the amide with the ⁇ - or ⁇ -carboxylic group (preferably, the ⁇ -carboxylic acid group of glutamic acid).
- glutamyl refers to the glutamate amino acid which has been derivatized as an ester or amide.
- ⁇ -glutamyl refers to a glutamate derivative formed at the ⁇ -carboxyl group of glutamic acid (ester or amide).
- ⁇ -glutamyl refers to a glutamate derivative formed at the ⁇ -carboxyl group of glutamic acid (ester or amide).
- N-glutamyl refers to a glutamate derivative formed at the amino group of glutamic acid (amide).
- Polyglutamic acid polypeptide residue refers to a polypeptide residue which contains more than one glutamic acid and preferably contains exclusively glutamic acid.
- the present invention relates to compounds according to the structure (I):
- the present compounds represent prodrug forms of intermediates that are believed to exhibit their activity through chloroethylation, methylation, and/or carbamoylation mechanisms, as illustrated in FIGS. 1 to 4 .
- the rationale for the new prodrug design was that enzyme-activated prodrugs could be converted into active alkylating species 1 and methyl isocyanate via a sequence of enzyme activation and prompt fragmentation.
- dephosphorylation can be accomplished by the AP enzyme activation to give intermediate 2 or 3 and subsequent benzyl group fragmentation generated the alkylating and carbamoylating species, as shown in FIG. 2 .
- AP-activated dephosphorylation and NR-activated reduction can afford intermediate 6 or 7, which can generate the alkylating and carbamoylating species via prompt fragmentation, as shown in FIG. 3 .
- cleavage of the compound can be catalyzed by the CPG2 or CPA enzyme to appropriately substituted phenol 10 and aromatic amine 11, and prompt fragmentation then produces the alkylating and carbamoylating species, as illustrated in FIG. 4 .
- the rate-determining step in this prodrug activation process would appear to be the P—O bond cleavage step, which is catalyzed by the AP enzyme.
- the subsequent fragmentation step is usually rapid.
- phosphate-linked prodrugs with longer half-lives in circulation, allowing them to act as an active alkylating species depot; or prodrugs with a different distribution than VNP40101M may hawe desirable properties.
- One approach to this goal is to slow down the dephosphorylation step, the rate-limiting step in the bio-activation of the phosphate-bearing SHPs by introducing bulky substituents at: the position alpha to the phosphate group.
- alkyl groups may impose steric hindrance by the close proximity to the P—O bond cleavage site, thereby slowing down the enzymatic dephosphorylation event.
- Another approach is to introduce electron-releasing or electron-withdrawing groups in the phenyl ring, which may effect the rate of the P—O bond cleavage.
- the subsequent fragmentation step also may be affected by substitution at the phenyl ring with electron-releasing or electron-withdrawing groups. Based upon these considerations, a number of phosphate-bearing SHPs were synthesized readily in good quantities and evaluated. The disodium salts of these prodrugs were very soluble in water.
- the compounds according to the present invention are primarily useful for their anti-neoplastic activity, including their activity against solid tumors.
- these compositions may also find use as intermediates in the chemical synthesis of other useful anti-neoplastic agents that are, in turn, useful as therapeutic agents or for other purposes.
- R is —CH 2 CH 2 Cl; R′ is —CH 3 ; R 2 is a phosphate group which can be free acid or salt (preferably Na).
- R 4 is Cl, F or Br (preferably Cl) when R 3 , R 5 and R 6 are H.
- R 5 is Cl, F or Br (preferably Cl, F) when R 3 , R 4 and R 6 are H.
- R 3 , R 4 , R 5 and R 6 are selected from F, Cl, Br or I (preferably, both substituents are the same and more preferably, both substituents are Cl), the other two of R 3 , R 4 , R 5 and R 6 are H.
- phosphate group can be free acid or salt (preferably Na).
- R 2 is NO 2 when R 4 is H.
- R 4 is NO 2 when R 2 is H.
- the acid-terminal can be free acid or salt (preferably Na).
- R 7 can be H or polyglutamyl.
- 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(substituted)hydrazines of Compounds 1 (19 and 20, R ⁇ CH 2 CH 2 Cl) are synthesized respectively by reacting 90CE with phosgene or its equivalents, such as triphosgene or trichloromethyl chloroformate (see, Majer, et al. J. Org. Chem. 1994, 59: 1937; and Pridgen, et al. J. Org. Chem.
- N-alkyl-N-benzylamine 15 or 16, where R′ is —CH 3 ; R 2 or R 4 is a phosphate group, such as diethyl phosphonooxy group; and unassigned groups of R 2 , R 3 , R 4 , R 5 and R 6 are each independently of the indicated structure or a related alkyl group, with the proviso that when any two of unassigned groups of R 2 , R 3 , R 4 , R 5 or R 6 are other than H, the other two of unassigned groups of R 2 , R 3 , R 4 , R 5 or R 6 are H).
- This coupling reaction can be achieved in high yield while using N,N,-diisopropylethylamine (DIEA) as a base and keeping the reaction at 0° C. in dry acetonitrile-dichloromethane solvent overnight.
- DIEA N,N,-diisopropylethylamine
- TMSBr trimethylsilyl bromide
- the phosphate free acid form 19 or 20 is treated with saturated sodium bicarbonate (NaHCO 3 ) solution to afford the corresponding disodium salt 21 or 22, respectively.
- Reversed phase column chromatography may be employed for purification of the above water-soluble SHPs (19-22).
- the N-benzyl-N-methylamines (15 and 16) can be prepared from the corresponding salicylaldehydes, salicylic acids, or 4-substituted phenols.
- Commercially available salicylaldehydes react with diethyl chlorophosphate to give their corresponding diethylphosphonoxy-benzaldehydes (23 or 24) under mild conditions.
- sodium borohydride as a reducing agent, the reductive amination of a respective 23 or 24 with methylamine affords the corresponding N-benzylmethylamine (15 or 16).
- salicylic acids are first reduced to the corresponding salicyl alcohols (25) using lithium aluminum hydride (LAH) as a reducing agent at reflux.
- LAH lithium aluminum hydride
- Selective phosphorylation (Silverberg, et al. Tetrahedron Lett. 1996, 37: 771) of the phenol of 25 was acheived with diethyl phosphite, carbon tetrachloride, DIEA and catalytic amounts of 4-dimethylaminopyridine (DMAP) to provide the benzyl alcohols (26).
- DMAP 4-dimethylaminopyridine
- PCC Pyridinium chlorochromate
- a similar synthetic strategy can also be employed for nitro-containing SHPs of Compounds II, as shown in FIG. 8 .
- reaction with diethyl chlorophosphate can give their corresponding diethylphosphonoxy-benzaldehydes (29 or 30) under mild conditions.
- sodium borohydride as a reducing agent
- the reductive amination of a respective 29 or 30 with methylamine affords the corresponding nitro-containing N-benzylmethylamine (31 or 32).
- This coupling reaction of 31 or 32 with 90CE can be achieved in high yield while using phosgene or its equivalents as a carbonyl coupling agent and DIEA as a base.
- the phosphate free acid form 35 or 36 is treated with saturated NaHCO 3 solution to afford the corresponding disodium salt 37 or 38, respectively.
- Reversed phase column chromatography may be employed for purification of the above water-soluble Compounds II (35-38).
- a pharmaceutically acceptable salt such as sodium salt 50, can be formed after further treatment with saturated NaHCO 3 solution.
- the crude product After synthesis, the crude product generally is purified by reversed phase column chromatography and lyophylization.
- compositions based upon the present novel chemical compounds comprise the above-described compounds in a therapeutically effective amount for the treatment of a condition or disease such as cancer, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.
- Certain of the compounds, in pharmaceutical dosage form, may be used as prophylactic agents for preventing a disease or condition from manifesting itself.
- the present compounds or their derivatives can be provided in the form of pharmaceutically acceptable salts.
- pharmaceutically acceptable salts or complexes refers to appropriate salts or complexes of the active compounds according to the present invention which retain the desired biological activity of the parent compound.
- Nonlimiting examples of such salts include the sodium and potassium salts of phosphate and glutamate, among others such as triethanolamine salt, triethylamine salt, lutidine salt, or other pharmaceutically acceptable salts known in the art.
- Modifications of the active compound can affect the solubility, pharmacokinetic parameters and rate of metabolism of the active species, thus providing control over the delivery of the active species. Further, the modifications can affect the anticancer activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivatives and testing the anticancer activity according to known methods well within the routineer's skill in the art.
- the compounds of this invention may be incorporated into formulations for all routes of administration including for example, oral and parenteral, including intravenous, intramuscular, intraperitoneal, intrabuccal, transdermal and in suppository form. Paranteral administration and in particular, intravenous or intramuscular administration is preferred.
- compositions based upon these novel chemical compounds comprise the above-described compounds in a therapeutically effective amount for treating cancer and other diseases and conditions which have been described herein, optionally in combination with a pharmaceutically acceptable additive, carrier and/or excipient.
- a therapeutically effective amount of one of more compounds according to the present invention will vary with the infection or condition to be treated, its severity, the treatment regiment to be employed, the pharmacokinetics of the agent used, as well as the patient (animal or human) treated.
- the compound according to the present invention is formulated preferably in admixture with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier In general, it is preferable to administer the pharmaceutical composition parenterally and in particular, in intravenously or intramuscular dosage form, but a number of formulations may be administered via other parenteral routes, such as transdermal, buccal, subcutaneous, suppository or other route, including via an oral route of administration.
- Intravenous and intramuscular formulations are preferably administered in sterile saline.
- one of ordinary skill in the art may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.
- the modification of the present compounds to render them more soluble in water or other vehicle may be easily accomplished by minor modifications (such as salt formulation, etc.) which are well within the ordinary skill in the art. It is also well within the routineer's skill to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect to the patient.
- the routineer will take advantage of favorable pharmacokinetic parameters of the prodrug forms of the present invention, where applicable, in delivering the present compounds to a targeted site within the host organism or patient to maximize the intended effects of the compound.
- Administration of the active compound may range from continuous (intravenous drip), including bolus administration, intravenously or intramuscularly even less frequently than once a day to several administrations per day and may include topical, parenteral, intravenous, intramuscular, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration, including, in certain instances, oral administration.
- continuous drip including bolus administration, intravenously or intramuscularly even less frequently than once a day to several administrations per day and may include topical, parenteral, intravenous, intramuscular, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration, including, in certain instances, oral administration.
- a therapeutically effective amount of one or more of the compounds according to the present invention is preferably intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques to produce a dose.
- a carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous or intramuscular.
- the carrier may comprise sterile water or aqueous sodium chloride solution in combination with other ingredients that aid dispersion, such as ethanol and other pharmaceutically acceptable solvents, including DMSO, among others.
- the compositions and carriers must also be sterilized.
- injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can be included the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelafing agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
- antibacterial agents such as benzyl alcohol or methyl parabens
- antioxidants such as ascorbic acid or sodium bisulfite
- any one or more of the usual pharmaceutical media may be used.
- suitable carriers and additives including water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used.
- suitable carriers and additives including starches, sugar carriers, such as dextrose, mannitol, lactose and related carriers, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used.
- the tablets or capsules may be enteric coated or sustained release by standard techniques.
- the active compounds may be prepared with carrier that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery system.
- a controlled release formulation including implants and microencapsulated delivery system.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polyactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared by dissolving appropriate lipid(s) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension. Other methods of preparation well known by those of ordinary skill may be used in this aspect of the present invention.
- the present compounds may be used to treat animals, and in particular, mammals, including humans, as patients.
- humans, equines, canines, bovines and other animals, and in particular, mammals, suffering from tumors, and in particular, cancer, or other diseases as described herein can be treated by administering to the patient an effective amount of one or more of the compounds according to the present invention or its derivative or a pharmaceutically acceptable salt thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known pharmaceutical agents, depending upon the disease to be treated.
- This treatment can also be administered in conjunction with other conventional cancer therapies, such as radiation treatment or surgery.
- the compositions according to the present invention may also be used to treat drug-resistant forms of tumors or cancer, especially those tumors or cancers which are resistant to traditional cancer drugs.
- the active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated.
- the present compounds are prodrug forms of reactive intermediates.
- the present compounds may be modified to other prodrug forms to take advantage of a particular route of administration of the active compounds.
- One of ordinary skill in the art will recognize how to readily modify the present compounds to alternative prodrug forms to facilitate delivery of active compounds to a targeted site within the patient.
- the individual of ordinary skill also will take advantage of favorable pharmacokinetic parameters of the prodrug forms, where applicable, in delivering the present compounds to a targeted site within the patient to maximize the intended anti-neoplastic effect of the compound.
- the amount of compound included within the therapeutically active formulations according to the present invention is an effective amount for treating cancer.
- a therapeutically effective amount of the compound according to the present invention in dosage form usually ranges from less than about 0.05 mg/kg to about 500 mg/kg of body weight of the patient to be treated, or considerably more, depending upon the compound used, the tumor type to be treated, the ability of the active compound to localize in the tissue to be treated, the route of administration and the pharmacokinetics of the compound in the patient.
- the compound is preferably administered in amounts ranging from about 0.05 mg/kg to about 250 mg/kg or more at one time.
- This dosage range generally produces effective blood level concentrations of active compound ranging from about 0.01 to about 500 micrograms per ml of blood in the patient to be treated.
- the duration of treatment may be for one or more days or may last for several months or considerably longer (years) depending upon the disease state treated.
- the compound is given to the patient at doses of 0.1 mg/kg to 100 mg/kg, twice per day to once per 14 days, for the duration of 1 week to 52 weeks.
- the concentration of active compound in the patient will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage given to the patient will be also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.
- the active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
- the active compound according to the present invention can be also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as other anticancer agents, and in certain instances depending upon the desired therapy or target, antibiotics, antifungals, antiflammatories, or antiviral compounds, among other agents.
- Compounds according to the present invention may be administered alone or in combination with other agents, especially including other compounds of the present invention.
- an effective amount of one or more of the compounds according to the present invention is co-administered along with an effective amount of at lease one additional anti-neoplastic/anticancer agent such as antimetabolites, Ara C, etoposide, doxorubicin, taxol, hydroxyurea, vincristine, cytoxan (cyclophosphamide) or mitomycin C, among numerous others, including topoisomerase I and topoisomerase II inhibitors, such as adriamycin, topotecan, campothecin and irinotecan, other agent such as gemcitabine and agents based upon campothecin and cis-platin.
- additional anti-neoplastic/anticancer agent such as antimetabolites, Ara C, etoposide, doxorubicin, taxol, hydroxyurea, vincristine
- the present compounds which act by a mechanism to damage DNA, will act synergistically with compounds that act by a mechanism to reduce or prevent DNA repair.
- the present compounds may be advantageously combined with any compound which acts by a mechanism to reduce or prevent DNA repair, especially including inhibitors of enzymes catalyzed DNA repair, such as inhibitors of ribonucleotide reductase (RR) and inhibitors of O 6 -alkylguanine-DNA alkyltransferase (AGT).
- RR ribonucleotide reductase
- AGT O 6 -alkylguanine-DNA alkyltransferase
- co-administer it is meant that the present compounds are administered to a patient such that the present compounds as well as the co-administered compound may be found in the patient's bloodstream at the same time, regardless when the compounds are actually administered, including simultaneously.
- the co-administration of the present compounds with traditional anticancer agents produces a synergistic (i.e., more than additive) result which is unexpected.
- the compounds according to the present invention are given either simultaneously or sequentially with antibodies (conjugated or unconjugated), viruses, or bacteria.
- the antibodies, viruses, or bacteria could carry enzymes or gene encoding enzymes that activate the compounds described in the present invention.
- the enzymes include but not limit to NR, CPG2 and CPA.
- the present compositions may be used to treat tumors and/or cancer which are resistant to one or more traditional anti-tumor/anti-cancer agents, such as those which have been described hereinabove.
- an effective amount of a composition is administered to a patient suffering from a drug-resistant tumor or cancer in order to treat the tumor or cancer.
- the present compositions may be administered alone or in combination with other effective anti-tumor/anti-cancer agents.
- the compounds according to the present invention primarily induce their therapeutic effect in treating malignant tumors by functional as combined chloroethylating and carbamoylating agents.
- 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazine (90CE).
- 90CE 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazine
- 16a (16.4 g, 60.5 mmol) and 90CE (15.1 g, 1.0 equivalent) gave phosphoric acid 2- ⁇ N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl ⁇ -phenyl ester diethyl ester (18a, 29.7 g, 89%).
- Compound 18a (10.5 g, 19.2 mmol) gave 20a (2.6 g, 27%) as a white powder.
- crude 43 was treated with saturated NaHCO 3 solution (200 mL) at room temperature for 2 hours.
- the resulting milky mixture was purified by RPFCC with de-ionized water. The fractions were monitored by HPLC and combined. After lyophylization, the disodium salt 44 (0.78 g, 20%) was obtained as a white powder.
- VNP40101M in water is 0.66 mg/mL at room temperature (Krishna, et al. AAPS PharrnsciTech 2001, 2: article 14).
- the solubility of the newly synthesized SHPs (19, 20a, 21, and 22a) is much higher than that of VNP40101M, as shown in Table 1.
- the stabilities of PAP-101M (19), OAP-101M (20a), and VNP40101M were investigated in potassium phosphate buffers (50 mM) at pH 3, 5, 7 and 9 and at room temperature (22-25° C.).
- 50 mM potassium phosphate buffers
- One sample was prepared at each pH for each drug; the initial drug concentration in each sample was 50 ⁇ g/mL.
- Table 3 shows the bioconversion of compounds 19 and 20a in the presence of AP (from bovine intestinal mucosa, Sigma) or human plasma. Each drug, at a final concentration of approximately 50 ⁇ g/mL, was incubated at 37° C. in 50 mM Tris buffered saline (pH 7.6) containing approximately 0.055 unit/mL of the phosphatase enzyme.
- AP bovine intestinal mucosa
- Table 3 shows the bioconversion of compounds 19 and 20a in the presence of AP (from bovine intestinal mucosa, Sigma) or human plasma.
- AP from bovine intestinal mucosa, Sigma
- Each drug at a final concentration of approximately 50 ⁇ g/mL, was incubated at 37° C. in 50 mM Tris buffered saline (pH 7.6) containing approximately 0.055 unit/mL of the phosphatase enzyme.
- the stability of compounds 19, 20a and VNP40101M was evaluated in 100% human plasma (pooled mixed gender, BioChemed) at a final concentration of 50 ⁇ g/mL.
- Each drug (19 or 20a) was incubated in human plasma at 37° C. for a maximum of two hours. Aliquots of the incubation mixture were taken at various time points and extracted with acetonitrile. The extract was separated by centrifugation and analyzed directly by HPLC.
- VNP40101M was incubated in human plasma at 37° C. for a maximum of one hour. At various time points, aliquots of the incubation mixture were removed and extracted with 0.5% H 3 PO 4 in acetonitrile. The extract was separated by centrifugation and analyzed directly by HPLC.
- the stability of each drug incubated in 50 mM Tris buffered saline (pH 7.6) instead of 100% human plasma was also determined.
- prodrugs 19 and 20a were conducted in female Sprague-Dawley rats (10 weeks old, 250 g, Charles River). Each prodrug was administered as a single bolus intravenous (iv) injection via the jugular vein at a dose of 50 mg per kg (mpk) of body weight. Blood samples were collected on the day of dosing at the following time points: pre-dose and approximately 2, 10, 30 min, 1, 2, and 24 hr, after dosing. At each time point, approximately 0.2 mL of blood was collected in a tube containing an anticoagulant (heparin), which was immediately acidified by adding 0.005 mL of a 2.0 M citric acid solution.
- heparin an anticoagulant
- the tube was inverted 4 to 6 times and immediately placed on ice.
- the blood samples were centrifuged within 30 min after blood collection at 3,000 rpm for 10-20 min at 2-8° C., and the plasma fraction was transferred to a labeled Nunc cryovial.
- the plasma samples were immediately frozen on dry ice and stored at ⁇ 20° C. until HPLC-UV analysis. Animals were euthanized with CO 2 inhalation after experiments.
- Bioanalytical methods were developed to quantify these prodrugs in rat plasma using HPLC-UV at either 220 nm or 230 nm. Each plasma sample (0.1 mL) was extracted with 0.2 mL of acetonitrile. The extract was separated by centrifugation and analyzed directly by HPLC-UV. HPLC calibration standards were prepared in control rat plasma and processed as above. The standard curve had a linear range of 1.0-50 ⁇ g/mL.
- VNP40101M and prodrugs were evaluated in both the B16-F10 murine melanoma and HTB177 human lung carcinoma models.
- B16-FI0 melanoma cells were implanted subcutaneously (5 ⁇ 10 5 cells) into C57BU 6 mice, which were randomized into groups of ten immediately after tumor cell implantation (Day 0). On Day 2, mice were injected intraperitoneally with either a bolus injection of 0.1 mL PBS or drug. The treatment was carried out weekly for four consecutive weeks.
- Tumor measurement in three dimensions was determined once a week with the formula L ⁇ H ⁇ W/2, where L, H, and W represent length, height, and width, respectively.
- L, H, and W represent length, height, and width, respectively.
- FIG. 11 B16-F10 tumors in the PBS control group grew exponentially, reaching a size around 4,000 mm 3 on Day 24.
- VNP40101M and tested prodrugs effectively inhibited the growth of B16-F 10 melanoma.
- tumor growth was inhibited by 81% in mice treated with 80 mg/kg of VNP40101M, and by 75 to 91% in mice treated with equal molar doses of the prodrugs.
- OAP-101M (20a) and OAP-Na-101M (22a) were the most efficacious; tumor growth inhibitions were 91% and 89.5%, respectively. The inhibitions were significantly (p ⁇ 0.05) higher than those in others groups. Tumor-bearing mice receiving OAP-101M (20a) also survived longer than that received other drugs ( FIG. 12 ). The toxicity of these drugs in mice was mild as determined by body weight loss and animal appearance, as illustrated in FIG. 13 . The anti-tumor effects of these prodrugs had also been investigated in HTB177 human lung carcinoma implanted in nu/nu CD-1 mice, as demonstrated in FIGS. 14 and 15 , and been shown that OAP-101M (20a) and OAP-Na-101M (22a) holdout promise as well.
- phosphate-bearing SHPs OAP-101M (20a) and OAP-Na-101M (22a) possesses the following characteristics: (a) highly water-soluble and stable in aqueous solution at pH 3 to 9; (b) its conversion can be catalyzed by alkaline phosphatase (AP); (c) has longer half-life in saline and in human plasma than PAP-101M (19) and VNP40101M; (d) has better in vivo PK profiles than PAP-101M; (e) has good anti-tumor activities against B16-F10 murine melanoma and HTB177 human lung carcinoma in mice as compared to PAP-101M (19), PAP-Na-101M (21) and VNP40101M; and (f) its sodium salt (22a) has even a higher water-solubility and similar anti-tumor activity than the free acid 20a.
- AP alkaline phosphatase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to compounds according to the structure (I):
Where R is —CH3 or —CH2CH2Cl; R′ is C1-C7 alkyl or —CH2CH2Cl; R2 or R4 is OP03H2, N02, OCO(Glu-OH), NHCO(Glu-OH), NHR7 and unassigned groups of R2, R3, R4, R5 and R6 are, independently, H, F, Cl, Br, I, OH, OP03H2, OCH3, CF3, OCF3, NO2, CN, SO2CH3, SO2CF3, COCH3, COOCH3, SCH3, SFs, NH2, NHR7, N(CH3)2, OPO3H2, or a C1-C7 alkyl group with the proviso that when any two of unassigned groups of R2, R3, R4, R5 or R6 are other than H, the other two of unassigned groups of R2, R3, R4, R5 or R6 are H. R7 is H or polyglutamyl as described. Phosphoric acid and glutamic acid can be a free acid or pharmaceutically acceptable salt thereof.
Where R is —CH3 or —CH2CH2Cl; R′ is C1-C7 alkyl or —CH2CH2Cl; R2 or R4 is OP03H2, N02, OCO(Glu-OH), NHCO(Glu-OH), NHR7 and unassigned groups of R2, R3, R4, R5 and R6 are, independently, H, F, Cl, Br, I, OH, OP03H2, OCH3, CF3, OCF3, NO2, CN, SO2CH3, SO2CF3, COCH3, COOCH3, SCH3, SFs, NH2, NHR7, N(CH3)2, OPO3H2, or a C1-C7 alkyl group with the proviso that when any two of unassigned groups of R2, R3, R4, R5 or R6 are other than H, the other two of unassigned groups of R2, R3, R4, R5 or R6 are H. R7 is H or polyglutamyl as described. Phosphoric acid and glutamic acid can be a free acid or pharmaceutically acceptable salt thereof.
Description
- The present invention relates to metabolically activated sulfonyl hydrazine prodrugs (SHPs) exhibiting anti-tumor activity in mammals. Methods of treating neoplasia, especially including cancer, using compounds according to the present invention, are additional aspects of the present invention.
- This invention was made with government support under grant number 1 R43 CA92968-01 awarded by the Department of Health and Human Services. As such, the government retains certain rights in the invention.
- Alkylating agents are among the most effective therapeutic agents currently available to treat different malignancies, and are widely used in the clinic (Katzung, In Basic & Clinical Pharmacology, 7th edition, 1998, Appleton & Lange, Stamford, 881). The high degree of cytotoxicity is attributed to the ability to induce DNA interstrand cross-linking thereby inhibiting replication (Rajski and Williams, Chem Reviews 1998, 98: 2723). Among the alkylating agents, the CNU (chloroethylnitrosourea) series have been widely used clinically to treat brain tumors, colon cancer and lymphomas (DeVita, et al. Cancer Res. 1965, 25: 1876; and Nissen, et al. Cancer 1979, 43: 31), however, their clinical usefulness is limited due to delayed and cumulative bone marrow depression and hepatic toxicity (Panasci, et al. Cancer Res. 1977, 37: 2615; and Gibson and Hickman, Biochem Pharmacol. 1982, 31: 2795).
- A series of 1,2-bis(sulfonyl)hydrazine prodrugs (SHPs) with the ability to generate chloroethylating and carbamoylating species, but lacking hydroxyethylating and vinylating species, generated by the CNUs had been developed recently (Sartorelli, et al. see U.S. Pat. No. 6,040,338; U.S. Pat. No. 5,637,619; U.S. Pat. No. 5,256,820; U.S. Pat. No. 5,214,068; U.S. Pat. No. 5,101,072; U.S. Pat. No. 4,849,563; and U.S. Pat. No. 4,684,747. The antitumor activity has been suggested to result from chloroethylating and subsequent cross-linking of DNA (Kohn, In Recent Results in Cancer Research, Eds. Carter, et al., 1981, Springer, Berlin, vol. 76: 141; and Shealy, et al., J Med Chem. 1984, 27: 664). The carbamoylating species (i.e., the isocyanate) can react with thiol and amine functionalities on proteins and inhibit DNA polymerase (Baril, et al. Cancer Res. 1975, 35: 1), the repair of DNA strand breaks (Kann, et al. Cancer Res. 1974, 34: 398) and RNA synthesis and processing (Kann, et al. Cancer Res. 1974, 34: 1982). However, hydroxyethylation of DNA is a carcinogenic and/or mutagenic event (Swenson, et al. J Natl Cancer Inst. 1979, 63: 1469).
- 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylaminocarbonyl)hydrazine (VNP40101M), the current lead compound in the SHP series, has lower toxicity to hosts and better anti-tumor activities against the L1210 murine leukemia, L1210/BCNU, L1210/CTX, L1210/MEL (1,3-bis(2-chloroethyl)-1-nitrosourea, cyclophosphamide and melphalan resistant sublines), P388 leukemia, M109 lung carcinoma, B16 melanoma, C26 colon carcinoma and U251 glioma than chloroethylnitrosourea (CNU) derivatives and other SHP analogs (Shyam, et al. J Med Chem. 1999, 42: 941). In addition, VNP4011M is effective in crossing the blood brain barrier (BBB) and eradicating leukemia cells implanted intracranially (>6.54 log cell kill), rivaling the efficacy of BCNU (Finch, et al. Cancer Biochem Biophys. 2001, 61: 3033).
- The anti-tumor activity of VNP40101M is probably due to the release of 90CE and methyl isocyanate. 90CE further fragments to yield methyl 2-chloroethyldiazosulfone (1)
FIG. 1 , a relatively specific O6-guanine chloroethylator, producing minimal alkylation of the N7-position of guanine (Penketh, et al. J Med Chem. 1994, 37: 2912; and Penketh, et al. Biochem Pharmacol. 2000, 59: 283). Methyl isocyanate released from VNP40101M has the ability to inhibit various DNA repair enzymes including O6-alkylguanine-DNA alkyltransferase leading to stabilization of the O6-alkylguanine monoalkyl species in DNA, which leads to a larger percentage of interstrand cross-links (Baril, et al. Cancer Res. 1975, 35: 1). - VNP40101M is currently in clinical trials in patients with solid tumors and hematologic malignancies. VNP40101M is not very soluble in aqueous solution; polyethylene glycol (PEG) and ethanol are included in the vehicle of the finished product to promote solubility. Both PEG and ethanol are acceptable vehicles for human use but may cause side effects such as hemolysis and phlebitis at high concentrations, as indicated in animal studies. VNP40101M is very well tolerated in humans and could be given at higher 110 doses, and could in theory produce a higher degree of efficacy, if PEG and ethanol could be eliminated from the vehicle. Therefore, our aim was to synthesize a series of SHPs that (a) were capable of improving its water-solubility and stability in aqueous solution at
pH 3 to 9; (b) were capable of forming chloroethylating species; (c) were devoid of hydroxyethylating activity; (d) were capable of forming methyl isocyanate; and (e) were capable of improving pharmacokinetic profiles (e.g., longer half-life in vivo). - The present inventors conceived that water-soluble enzymatically-activated SHPs (I) might satisfy the above conditions. An example of such an SHP would be the phosphate containing derivatives shown in
FIG. 2 for the following reasons: -
- (a) In general, a phosphate-bearing analog, including its salt form may have good water-solubility and stability at neutral pH;
- (b) The bioconversion of compounds of general structure I is believed to proceed via alkaline phosphatase (AP) cleavage of the oxygen-phosphorous bond to form the phenol intermediate, which may subsequently undergo fragmentation resulting in the formation of chloroethylating or methylating species and carbamoylating agent without generating hydroxyethylating agent, as shown in
FIGS. 1 and 2 .
- (c) The bioconversion of compounds I may also generate a quinone methide which itself can cause damage to DNA and thereby contribute to inhibition of cellular replication (Lin, et al. J Med Chem. 1986, 29: 84).
- (d) Compounds I may be considered as prodrugs of VNP40101M that has been identified as an alkylating agent against a broad anticancer spectrum of neoplastic disease states, including, for example, numerous solid tumors. Thus, compounds I may generate the same active species as VNP40101M.
- Further examples of bioactivated prodrugs are shown in
FIGS. 3 and 4 . The nitro analogs shown inFIG. 3 are examples of compounds that would be both water soluble and selectively activated under conditions of hypoxia. Release of VNP40101M would only occur on reduction of the nitro group under conditions of hypoxia. Compounds II would be reduced by nitroreductase (NR) to the corresponding amino analogs, which would be subsequently fragmented into VNP40101M and a quinone-imine methide. NR, an enzyme isolated from E. Coli or Bacillus spp., is widely used in ADEPT (antibody-directed enzyme prodrug therapy) or GDEPT (gene-directed enzyme prodrug therapy) for cancer therapy (Anlezark, et al. WO93/08288, 1993). -
FIG. 4 illustrates the use of peptidases to generate VNP40101M intratumorally. Cleavage of compounds derived from conjugation of glutamyl residues to appropriately substituted phenols and aromatic amines by carboxypeptidases such as carboxypeptidase G2 (CPG2) and carboxypeptidase A (CPA) has been shown previously. CPG2, an enzyme isolated from Pseudomonas, is capable of removing glutamate residues from folates and methotrexate. It has been employed in the ADEPT or GDEPT system to activate prodrugs containing glutamate residues (Bagshawe, et al. WO88/07378, 1988; Springer, et al. - U.S. Pat. No. 6,025,340, 2000; Springer, et al. U.S. Pat. No. 6,004,550, 1999). CPA from bovine pancreas readily cleaves drug α-peptides (derivatives in which an amino acid is linked to the α-carboxyl group of the glutamate moiety). Also, it has been employed in the ADEPT (Wolfe, et al. Bioconjug Chem. 1999, 10: 38; Huennekens, Adv Enzyme Regul. 1997, 37: 77; and Vitols, et al. Cancer Res. 1995, 55: 478). As shown in
FIG. 4 , Compounds III and Compounds IV would be cleaved by the corresponding CPG2 or CPA, which may either be introduced as an antibody conjugate or a transgene (Pawelek, et al. U.S. Pat. No. 6,190,657, 2001), to form VNP40101M and a quinone methide or quinone-imine methide. - In one aspect, an object of the present invention is to provide compounds, pharmaceutical compositions and methods for the treatments of neoplasia, including animal and human cancer.
- In another aspect of the invention, an object of the present invention is to provide methods of treating neoplasia utilizing compositions that exhibit favorable and enhanced characteristics of activity, pharmacokinetics, bioavailability and reduced toxicity.
- It is yet another object of the invention to provide compositions and methods for the treatment of cancers which are resistant to treatment with traditional chemotherapeutic agents.
- One or more of these and/or other objects of the invention may be readily gleaned from the description of the invention that follows.
-
- Where R is —CH3 or —CH2CH2Cl;
- R′ is C1-C7 alkyl or —CH2CH2Cl; one of R2 or R4, but not both, is selected from OPO3H2, NO2, OCO(Glu), NHCO(Glu) and NHR7 and the other of R2 or R4 hich is unassigned, and R3, R5 and R6, are, independently selected from H, F, Cl, Br, I, OH, OPO3H2, OCH3, CF3, OCF3, NO2, CN, SO2CH3, SO2CF3, COCH3, COOCH3, SCH3, SF5, NHR8, N(R9)2, OPO3H2 and C1-C7 alkyl, with the proviso that at least two of R2, R3, R4, R5 and R6 are H;
- R7 is H, glutamyl, preferably α-glutamyl(—COCH(NH2)CH2CH2CO2H) or a polyglutamic acid polypeptide residue (—COCH(NHR7a)CH2CH2CO2H where R7a is glutamyl (preferably, α-glutamyl) or a polyglutamic acid polypeptide residue) having from 1 to 50 peptide linkages, preferably from 2 to 10 peptide linkages;
- R8 is H or C1-C7 alkyl; and
- R9 is CH3 or CH2CH3. The phosphoric acid and/or glutamic acid substituents can be in the free acid form or a pharmaceutically acceptable salt thereof.
- In certain preferred aspects of the present invention, preferred agents in the class of Compounds I are ortho-phosphate-bearing series where R is —CH2CH2Cl; R′ is —CH3; R2 is a phosphate group which can be the free acid or its pharmaceutically acceptable salt (preferably Na). In particularly preferred aspects of the ortho-phosphate-bearing SHPs, R4 is Cl, F or Br (preferably Cl) when R3, R5 and R6 are H. In other preferred aspects of the ortho-phosphate-bearing SHPs, R5 is Cl, F or Br (preferably Cl, F) when R3, R4 and R6 are H. Still in other preferred aspects of the ortho-phosphate-bearing SHPs, two of R3, R4, R5 and R6 are selected from F, Cl, Br or I (preferably, both substituents are the same and more preferably, both substituents are Cl), the other two of R3, R4, R5 and R6 are H.
- Preferred agents in the class of Compounds II are meta-phosphate-bearing nitro-containing analogs of SHPs. The phosphate group can be the free acid or its pharmaceutically acceptable salt (preferably Na). In a particularly preferred aspects of the nitro-containing SHPs, R2 is NO2 when R4 is H. In other preferred aspects of the nitro-containing SHPs, R4 is NO2 when R2 is H.
- Preferred agents in the classes of Compounds III and IV are glutamyl residue-conjugated analogs of SHPs. In particularly preferred aspects of both of these SHPs, the acid-terminal can be the free acid or its pharmaceutically acceptable salt (preferably, Na). In still other preferred aspects of Compounds IV, R7 can be H or a polyglutamic acid polypeptide residue.
- Compounds according to the present invention and especially the preferred compositions according to the present invention, as set forth above, are extremely effective compounds for the treatment of neoplasia. They also exhibit at least one or more improvements such as an enhanced anti-neoplasia activity, a reduced toxicity, a higher water-solubility, or a more favorable pharmacokinetic profile compared to VNP40101M. Thus, preferred compounds according to the present invention could have a higher therapeutic index (i.e., a better benefit/risk ratio), than VNP40101M.
- Compounds according to the present invention may be used in pharmaceutical compositions for the treatment of cancer, as well as a number of other conditions and/or disease states. Examples according to the present invention may be as intermediates in the synthesis of other compounds exhibiting biological activity as well as standards for determining the biological activity of the present compounds. In some applications, the present compounds may be used for treating microbial infections, especially including viral, bacterial, and fungal infections. These compounds comprise an effective amount of any one or more of the compounds disclosed hereinabove, optionally in combination with a pharmaceutically acceptable additive, carrier, or excipient.
- A further aspect of the present invention relates to the treatment of cancer, comprising administering to a patient in need thereof an effective amount of a compound as described hereinabove, optionally in combination with a pharmaceutically acceptable additive, carrier, or excipient. The present invention also relates to methods for treating neoplasia in mammals comprising administering an effective amount of a compound as described hereinabove to a patient suffering from cancer. The treatment of solid malignant tumors, leukemia, and lymphomas comprising administering to a patient an anti-tumor effective amount of one or more these agents is a preferred embodiment of the present invention. The treatment of various other related disease states may also be effected using the compounds of the present invention. This method may also be used in comparison tests such as assays for determining the activities of related analogs as well as for determining the susceptibility of a patient's cancer to one or more of the compounds according to the present invention.
-
FIG. 1 is a pictorial representation of a suggested mechanism of activation of VNP40101M. -
FIGS. 2, 3 and 4 are pictorial representations of the certain chemical embodiments and their proposed mechanisms of activation according to the present invention. -
FIGS. 5-9 are pictorial representations of chemical schemes for synthesizing compounds according to the present invention. -
FIGS. 10-15 are pictorial representations of experimental results which are presented in the present application related to the efficacy and toxicity of certain preferred embodiments according to the present invention. - The following terms shall be used throughout the specification to describe the present invention.
- The term “patient” is used throughout the specification to describe an animal, including a mammal and preferably a human, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided. For treatment of infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal. Preferably, in most aspects of the present invention, patients are human patients.
- The term “effective amount” is used throughout the specification to describe concentrations or amounts of compounds according to the present invention which may be used to produce an intended result within its use in context, generally, a favorable change in the disease or condition treated, whether that change is a remission, a decrease in growth or size of cancer or a tumor, a favorable physiological result, a reduction in the growth or elaboration of a tumor, cancerous tissue, or the like, depending upon the disease or condition treated.
- The term “neoplasia” is used throughout the specification to describe the pathological process that results in the formation and growth of a neoplasm, i.e., an abnormal tissue that grows by cellular proliferation more rapidly than normal tissue and continues to grow after the stimuli that initiated the new growth cease. Neoplasia could be a distinct mass of tissue that may be benign (benign tumor) or malignant (carcinoma). As used herein, the term neoplasia is used to describe all cancerous disease states and embraces or encompasses the pathological process associated with malignant hematogenous, ascitic, and solid tumors.
- The term “cancer” and the term “tumor” used in this application is interchangeable with the term “neoplasia”.
- Cancer which may be treated using compositions according to the present invention include, for example, stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/CNS, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, melanoma, acute lymphocytic leukemia, acute myelogenous leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' Tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, kidney, lymphoma, among others. The treatment of tumors comprising administering to a patient an anti-tumor effective amount of one or more these agents is a preferred embodiment of the present invention.
- The term “alkyl” is used throughout the specification to describe a fully saturated hydrocarbon radical containing between one to seven carbon units. Alkyl groups for use in the present invention include linear, branched-chain or cyclic groups, such as preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, cyclohexyl, methylcyclopropyl and methylcyclohexyl.
- The term “salt” is used throughout the specification to describe any salt consistent with the use of the compounds according to the present invention. In the case where the compounds are used in pharmaceutical indications, including the treatment of cancer, the term “salt” shall mean a pharmaceutically acceptable salt, consistent with the use of the compounds as pharmaceutical agents.
- The term “glu” or (“Glu)” used in chemical formulas according to the present invention refers to a glutamic acid residue or derivative within context which may be bonded on its amino group with another carboxyl group (e.g., RCOOH) or on one of its carboxyl groups with a hydroxyl group or an amino group. Glutamic acid (HOOCCH(NH2)CH2CH2COOH) has two reactive carboxylic acid groups and a reactive amino group, which may be used to form glutamyl residues in compounds according to the present invention. As indicated by the chemical structure, glutamic acid may be bonded on one of the two carboxyl groups with another amino group (RNH2) or a hydroxyl group (ROH) to form the corresponding α-glutamyl or γ-glutamyl amide or ester compound.
- Alternatively, glutamate may be bonded on its amino group with a carboxyl group forming an N-glutamyl amide derivative. In the present compounds, a single glutamyl residue may be present, as well as a polyglutamyl polypeptide residue, which is a polypeptide formed from two or more glutamate amino acids. The term OCO(Glu) is representative of glutamyl residue (α- or γ-) which is bonded to a free hydroxyl group to form the ester with the α- or γ-carboxylic group (preferably, the αcarboxylic acid group of glutamic acid). The term NHCO(Glu) is representative of a glutamyl residue (α- or γ-) which is bonded to a free amine group to form the amide with the α- or γ-carboxylic group (preferably, the α-carboxylic acid group of glutamic acid). The term “glutamyl” refers to the glutamate amino acid which has been derivatized as an ester or amide. α-glutamyl refers to a glutamate derivative formed at the α-carboxyl group of glutamic acid (ester or amide). γ-glutamyl refers to a glutamate derivative formed at the γ-carboxyl group of glutamic acid (ester or amide). N-glutamyl refers to a glutamate derivative formed at the amino group of glutamic acid (amide). Polyglutamic acid polypeptide residue refers to a polypeptide residue which contains more than one glutamic acid and preferably contains exclusively glutamic acid.
-
- Where R is —CH3 or —CH2CH2Cl;
- R′ is C1-C7 alkyl or —CH2CH2Cl; one of R2 or R4, but not both, is selected from OPO3H2, NO2, OCO(Glu), NHCO(Glu) and NHR7 and the other of R2 or R4 which is unassigned, and R3, R5 and R6, are, independently selected from H, F, Cl, Br, I, OH, OPO3H2, OCH3, CF3, OCF3, NO2, CN, SO2CH3, SO2CF3, COCH3, COOCH3, SCH3, SF5, NHR8, N(R9)2, OPO3H2 and C1-C7 alkyl, with the proviso that at least two of R2, R3, R4, R5 and R6 are H;
- R7 is H, glutamyl, preferably, α-glutamyl(—COCH(NH2)CH2CH2CO2H) or a polyglutamic acid polypeptide residue —COCH(NHR7a)CH2CH2CO2H where R7a is glutamyl (preferably, α-glutamyl) or a polyglutamic acid polypeptide residue having from 1 to 50 peptide linkages, preferably from 2 to 10 peptide linkages;
- R8 is H or C1-C7 alkyl; and
- R9 is CH3 or CH2CH3. Phosphoric acid and glutamic acid (glutamyl) can be a free acid or a pharmaceutically acceptable salt thereof.
- The present compounds represent prodrug forms of intermediates that are believed to exhibit their activity through chloroethylation, methylation, and/or carbamoylation mechanisms, as illustrated in FIGS. 1 to 4. The rationale for the new prodrug design was that enzyme-activated prodrugs could be converted into active alkylating
species 1 and methyl isocyanate via a sequence of enzyme activation and prompt fragmentation. For Compounds I, dephosphorylation can be accomplished by the AP enzyme activation to give intermediate 2 or 3 and subsequent benzyl group fragmentation generated the alkylating and carbamoylating species, as shown inFIG. 2 . For Compounds II, AP-activated dephosphorylation and NR-activated reduction can afford intermediate 6 or 7, which can generate the alkylating and carbamoylating species via prompt fragmentation, as shown inFIG. 3 . For Compounds III and IV, cleavage of the compound can be catalyzed by the CPG2 or CPA enzyme to appropriately substitutedphenol 10 andaromatic amine 11, and prompt fragmentation then produces the alkylating and carbamoylating species, as illustrated inFIG. 4 . - While not being limited by way of theory, it is theorized that the rate-determining step in this prodrug activation process would appear to be the P—O bond cleavage step, which is catalyzed by the AP enzyme. The subsequent fragmentation step is usually rapid. It is possible that phosphate-linked prodrugs with longer half-lives in circulation, allowing them to act as an active alkylating species depot; or prodrugs with a different distribution than VNP40101M, may hawe desirable properties. One approach to this goal is to slow down the dephosphorylation step, the rate-limiting step in the bio-activation of the phosphate-bearing SHPs by introducing bulky substituents at: the position alpha to the phosphate group. These alkyl groups may impose steric hindrance by the close proximity to the P—O bond cleavage site, thereby slowing down the enzymatic dephosphorylation event. Another approach is to introduce electron-releasing or electron-withdrawing groups in the phenyl ring, which may effect the rate of the P—O bond cleavage. In addition, the subsequent fragmentation step also may be affected by substitution at the phenyl ring with electron-releasing or electron-withdrawing groups. Based upon these considerations, a number of phosphate-bearing SHPs were synthesized readily in good quantities and evaluated. The disodium salts of these prodrugs were very soluble in water.
- The compounds according to the present invention are primarily useful for their anti-neoplastic activity, including their activity against solid tumors. In addition, these compositions may also find use as intermediates in the chemical synthesis of other useful anti-neoplastic agents that are, in turn, useful as therapeutic agents or for other purposes.
- In preferred Compounds I according to the present invention, R is —CH2CH2Cl; R′ is —CH3; R2 is a phosphate group which can be free acid or salt (preferably Na). In particularly preferred aspects of the ortho-phosphate-bearing SHPs, R4 is Cl, F or Br (preferably Cl) when R3, R5 and R6 are H. In other preferred aspects of the ortho-phosphate-bearing SHPs, R5 is Cl, F or Br (preferably Cl, F) when R3, R4 and R6 are H. Still in other preferred aspects of the ortho-phosphate-bearing SHPs, two of R3, R4, R5 and R6 are selected from F, Cl, Br or I (preferably, both substituents are the same and more preferably, both substituents are Cl), the other two of R3, R4, R5 and R6 are H.
- In preferred Compounds II according to the present invention, they are meta-phosphate-bearing nitro-containing analogs of SHPs. The phosphate group can be free acid or salt (preferably Na). In particularly preferred aspects of the nitro-containing SHPs, R2 is NO2 when R4 is H. In other preferred aspects of the nitro-containing SHPs, R4 is NO2 when R2 is H.
- In preferred Compounds III and IV according to the present invention, they are glutamyl residue-conjugated analogs of SHPs. In particularly preferred aspects of the both SHPs, the acid-terminal can be free acid or salt (preferably Na). Still in preferred aspects of Compounds IV, R7 can be H or polyglutamyl.
- Compounds according to the present invention are synthesized by the adaptation of techniques that are well known in the art and are derived from 90CE. The synthesis of 90CE is shown in
FIG. 5 (see Sartorelli, et al. U.S. Pat. No. 4,684,747, 1987, relevant portions of which are incorporated by reference herein). - As demonstrated in
FIG. 6 , 2-aminocarbonyl-1,2-bis(methylsulfonyl)-1-(substituted)hydrazines of Compounds 1 (19 and 20, R≡CH2CH2Cl) are synthesized respectively by reacting 90CE with phosgene or its equivalents, such as triphosgene or trichloromethyl chloroformate (see, Majer, et al. J. Org. Chem. 1994, 59: 1937; and Pridgen, et al. J. Org. Chem. 1989, 54: 3231), and a further condensation in situ with an appropriate N-alkyl-N-benzylamine (15 or 16, where R′ is —CH3; R2 or R4 is a phosphate group, such as diethyl phosphonooxy group; and unassigned groups of R2, R3, R4, R5 and R6 are each independently of the indicated structure or a related alkyl group, with the proviso that when any two of unassigned groups of R2, R3, R4, R5 or R6 are other than H, the other two of unassigned groups of R2, R3, R4, R5 or R6 are H). This coupling reaction can be achieved in high yield while using N,N,-diisopropylethylamine (DIEA) as a base and keeping the reaction at 0° C. in dry acetonitrile-dichloromethane solvent overnight. Following deprotection of 17 or 18 with trimethylsilyl bromide (TMSBr) (Matulic-Adamic, et al. J Org Chem. 1995, 60: 2563), the phosphatefree acid form disodium salt 21 or 22, respectively. Reversed phase column chromatography may be employed for purification of the above water-soluble SHPs (19-22). - As shown in
FIG. 7 , the N-benzyl-N-methylamines (15 and 16) can be prepared from the corresponding salicylaldehydes, salicylic acids, or 4-substituted phenols. Commercially available salicylaldehydes react with diethyl chlorophosphate to give their corresponding diethylphosphonoxy-benzaldehydes (23 or 24) under mild conditions. Using sodium borohydride as a reducing agent, the reductive amination of a respective 23 or 24 with methylamine affords the corresponding N-benzylmethylamine (15 or 16). Commercially available salicylic acids are first reduced to the corresponding salicyl alcohols (25) using lithium aluminum hydride (LAH) as a reducing agent at reflux. Selective phosphorylation (Silverberg, et al. Tetrahedron Lett. 1996, 37: 771) of the phenol of 25 was acheived with diethyl phosphite, carbon tetrachloride, DIEA and catalytic amounts of 4-dimethylaminopyridine (DMAP) to provide the benzyl alcohols (26). Pyridinium chlorochromate (PCC)-oxidation (Kasmai, et al. J. Org. Chem. 1995, 60: 2267) is used for the transformation of the benzyl alcohols (26) to the benzaldehydes (24). Under Duff formylation conditions using hexamethylene-tetraamine (HMTA) in trifluoroacetic acid (TFA) at reflux (Lindoy, et al., Synthesis 1998, 1029), the corresponding salicylaldehydes (27 or 28) were obtained from commercially available 4-subtituted phenols, and then were converted to 24 and 16 via similar phosphorylation and reductive amination steps described above. The synthesis of the appropriate N-alkyl-N-benzylamine derivatives for use in these reaction schemes is well known in the art and uses standard chemical techniques. - A similar synthetic strategy can also be employed for nitro-containing SHPs of Compounds II, as shown in
FIG. 8 . Using commercially available nitrobenzaldehydes as the starting material, reaction with diethyl chlorophosphate can give their corresponding diethylphosphonoxy-benzaldehydes (29 or 30) under mild conditions. Using sodium borohydride as a reducing agent, the reductive amination of a respective 29 or 30 with methylamine affords the corresponding nitro-containing N-benzylmethylamine (31 or 32). This coupling reaction of 31 or 32 with 90CE can be achieved in high yield while using phosgene or its equivalents as a carbonyl coupling agent and DIEA as a base. Following TMSBr-deprotection of 33 or 34, the phosphatefree acid form 35 or 36 is treated with saturated NaHCO3 solution to afford the correspondingdisodium salt 37 or 38, respectively. Reversed phase column chromatography may be employed for purification of the above water-soluble Compounds II (35-38). - Preparation of the glutamic acid substituted phenols of Compounds III is outlined in
FIG. 9 . Glutamic acid di-tert-butyl ester (39) reacted with phosgene or its equivalents, followed by condensation in situ with 4-hydroxy-benzaldehyde at 0° C. overnight to give the glutamate-bearingbenzaldehyde 40 in good yield. Reductive amination of 40 provided thesecondary amine 41 in fair yield. Reaction ofcompound 41 with phosgene at 0° C., followed by condensation in situ with 90CE gave 42 successfully. Following a published procedure (Mann, et al. Tetrahedron 1990, 46: 5377), deprotection of 42 was easily accomplished by treatment with formic acid to afford thefree acid 43. Further treatment of 43 with saturated NaHCO3 solution or an appropriate amine can provide a respective water-soluble glutamate 44 such as disodium salt, triethanolamine salt, triethylamine salt, or lutidine salt. - The synthesis of glutamyl substituted aromatic amino analogs (Compounds IV) is illustrated in
FIG. 10 . Following a literature procedure (Jones, et al. Bio-org Med Chem Lett. 2000, 10: 1987), commercially available N-Boc-glutamic acid 5-tert-butyl ester (45) can react with 4-aminobenzyl alcohol to form theamide 46 in high yield, using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole (HOBT) as promoters under mild conditions. As an alternative to prepare a N-benzyl-N-methylamine by PCC-oxidation and reductive amination, a published procedure for the one-pot conversion of thebenzyl alcohol 46 into thesecondary amine 47 is employed which utilizes manganese dioxide in the presence of sodium borohydride (Kanno, et al. Tetrahedron Lett. 2002, 43: 7337). Reaction of theamine 47 with phosgene at 0° C., followed by condensation in situ with 90CE can generate 48 successfully, using DIEA as promoter. Deprotection of 48 can be easily accomplished by treatment with a dilute hydrochloric acid to afford thefree acid 49. - Finally, a pharmaceutically acceptable salt, such as
sodium salt 50, can be formed after further treatment with saturated NaHCO3 solution. - After synthesis, the crude product generally is purified by reversed phase column chromatography and lyophylization. The synthesis evidences that the SHPs of the present invention may be readily converted to their corresponding phosphate salts. Modification of the disclosed chemical synthetic methods may be readily made by those of ordinary skill in the art in order to provide alternative synthetic pathways to the present compounds.
- Pharmaceutical compositions based upon the present novel chemical compounds comprise the above-described compounds in a therapeutically effective amount for the treatment of a condition or disease such as cancer, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.
- Certain of the compounds, in pharmaceutical dosage form, may be used as prophylactic agents for preventing a disease or condition from manifesting itself.
- The present compounds or their derivatives can be provided in the form of pharmaceutically acceptable salts. As used therein, the term pharmaceutically acceptable salts or complexes refers to appropriate salts or complexes of the active compounds according to the present invention which retain the desired biological activity of the parent compound.
- Nonlimiting examples of such salts include the sodium and potassium salts of phosphate and glutamate, among others such as triethanolamine salt, triethylamine salt, lutidine salt, or other pharmaceutically acceptable salts known in the art. Modifications of the active compound can affect the solubility, pharmacokinetic parameters and rate of metabolism of the active species, thus providing control over the delivery of the active species. Further, the modifications can affect the anticancer activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivatives and testing the anticancer activity according to known methods well within the routineer's skill in the art.
- The compounds of this invention may be incorporated into formulations for all routes of administration including for example, oral and parenteral, including intravenous, intramuscular, intraperitoneal, intrabuccal, transdermal and in suppository form. Paranteral administration and in particular, intravenous or intramuscular administration is preferred.
- Pharmaceutical compositions based upon these novel chemical compounds comprise the above-described compounds in a therapeutically effective amount for treating cancer and other diseases and conditions which have been described herein, optionally in combination with a pharmaceutically acceptable additive, carrier and/or excipient. One of ordinary skill in the art will recognize that a therapeutically effective amount of one of more compounds according to the present invention will vary with the infection or condition to be treated, its severity, the treatment regiment to be employed, the pharmacokinetics of the agent used, as well as the patient (animal or human) treated.
- In the pharmaceutical aspect according to the present invention, the compound according to the present invention is formulated preferably in admixture with a pharmaceutically acceptable carrier. In general, it is preferable to administer the pharmaceutical composition parenterally and in particular, in intravenously or intramuscular dosage form, but a number of formulations may be administered via other parenteral routes, such as transdermal, buccal, subcutaneous, suppository or other route, including via an oral route of administration. Intravenous and intramuscular formulations are preferably administered in sterile saline. Of course, one of ordinary skill in the art may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity. In particular, the modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (such as salt formulation, etc.) which are well within the ordinary skill in the art. It is also well within the routineer's skill to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect to the patient.
- The routineer will take advantage of favorable pharmacokinetic parameters of the prodrug forms of the present invention, where applicable, in delivering the present compounds to a targeted site within the host organism or patient to maximize the intended effects of the compound.
- Administration of the active compound may range from continuous (intravenous drip), including bolus administration, intravenously or intramuscularly even less frequently than once a day to several administrations per day and may include topical, parenteral, intravenous, intramuscular, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal and suppository administration, among other routes of administration, including, in certain instances, oral administration.
- To prepare the pharmaceutical compositions according to the present invention, a therapeutically effective amount of one or more of the compounds according to the present invention is preferably intimately admixed with a pharmaceutically acceptable carrier according to conventional pharmaceutical compounding techniques to produce a dose. A carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., intravenous or intramuscular. In preparing pharmaceutical compositions in the appropriate dosage form, any of the usual pharmaceutical media may be used. For parenteral formulations, the carrier may comprise sterile water or aqueous sodium chloride solution in combination with other ingredients that aid dispersion, such as ethanol and other pharmaceutically acceptable solvents, including DMSO, among others. Of course, where solutions are to be used and maintained as sterile, the compositions and carriers must also be sterilized. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can be included the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelafing agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. If administered intravenously, preferred carriers include, for example, physiological saline or phosphate buffered saline (PBS).
- In preparing pharmaceutical compositions in oral dosage form, any one or more of the usual pharmaceutical media may be used. Thus, for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives including water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used. For solid oral preparations such as powders, tablets, capsules, and for solid preparations such as suppositories, suitable carriers and additives including starches, sugar carriers, such as dextrose, mannitol, lactose and related carriers, diluents, granulating agents, lubricants, binders, disintegrating agents and the like may be used. If desired, the tablets or capsules may be enteric coated or sustained release by standard techniques.
- In one embodiment, the active compounds may be prepared with carrier that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery system. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polyactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- Liposomal suspensions may also be pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art. For example, liposome formulations may be prepared by dissolving appropriate lipid(s) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension. Other methods of preparation well known by those of ordinary skill may be used in this aspect of the present invention.
- The present compounds may be used to treat animals, and in particular, mammals, including humans, as patients. Thus, humans, equines, canines, bovines and other animals, and in particular, mammals, suffering from tumors, and in particular, cancer, or other diseases as described herein, can be treated by administering to the patient an effective amount of one or more of the compounds according to the present invention or its derivative or a pharmaceutically acceptable salt thereof optionally in a pharmaceutically acceptable carrier or diluent, either alone, or in combination with other known pharmaceutical agents, depending upon the disease to be treated. This treatment can also be administered in conjunction with other conventional cancer therapies, such as radiation treatment or surgery. In a preferred aspect, the compositions according to the present invention may also be used to treat drug-resistant forms of tumors or cancer, especially those tumors or cancers which are resistant to traditional cancer drugs.
- The active compound is included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to deliver to a patient a therapeutically effective amount for the desired indication, without causing serious toxic effects in the patient treated.
- The present compounds are prodrug forms of reactive intermediates. In certain pharmaceutical dosage forms, the present compounds may be modified to other prodrug forms to take advantage of a particular route of administration of the active compounds. One of ordinary skill in the art will recognize how to readily modify the present compounds to alternative prodrug forms to facilitate delivery of active compounds to a targeted site within the patient. The individual of ordinary skill also will take advantage of favorable pharmacokinetic parameters of the prodrug forms, where applicable, in delivering the present compounds to a targeted site within the patient to maximize the intended anti-neoplastic effect of the compound.
- The amount of compound included within the therapeutically active formulations according to the present invention is an effective amount for treating cancer. In general, a therapeutically effective amount of the compound according to the present invention in dosage form usually ranges from less than about 0.05 mg/kg to about 500 mg/kg of body weight of the patient to be treated, or considerably more, depending upon the compound used, the tumor type to be treated, the ability of the active compound to localize in the tissue to be treated, the route of administration and the pharmacokinetics of the compound in the patient. In the case of treating cancer, the compound is preferably administered in amounts ranging from about 0.05 mg/kg to about 250 mg/kg or more at one time. This dosage range generally produces effective blood level concentrations of active compound ranging from about 0.01 to about 500 micrograms per ml of blood in the patient to be treated. The duration of treatment may be for one or more days or may last for several months or considerably longer (years) depending upon the disease state treated. In a more preferred embodiment, the compound is given to the patient at doses of 0.1 mg/kg to 100 mg/kg, twice per day to once per 14 days, for the duration of 1 week to 52 weeks.
- The concentration of active compound in the patient will depend on absorption, distribution, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage given to the patient will be also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
- The active compound according to the present invention can be also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as other anticancer agents, and in certain instances depending upon the desired therapy or target, antibiotics, antifungals, antiflammatories, or antiviral compounds, among other agents.
- Compounds according to the present invention may be administered alone or in combination with other agents, especially including other compounds of the present invention. In these aspects according to the present invention, an effective amount of one or more of the compounds according to the present invention is co-administered along with an effective amount of at lease one additional anti-neoplastic/anticancer agent such as antimetabolites, Ara C, etoposide, doxorubicin, taxol, hydroxyurea, vincristine, cytoxan (cyclophosphamide) or mitomycin C, among numerous others, including topoisomerase I and topoisomerase II inhibitors, such as adriamycin, topotecan, campothecin and irinotecan, other agent such as gemcitabine and agents based upon campothecin and cis-platin. In theory, the present compounds, which act by a mechanism to damage DNA, will act synergistically with compounds that act by a mechanism to reduce or prevent DNA repair. Thus, the present compounds may be advantageously combined with any compound which acts by a mechanism to reduce or prevent DNA repair, especially including inhibitors of enzymes catalyzed DNA repair, such as inhibitors of ribonucleotide reductase (RR) and inhibitors of O6-alkylguanine-DNA alkyltransferase (AGT). By “co-administer” it is meant that the present compounds are administered to a patient such that the present compounds as well as the co-administered compound may be found in the patient's bloodstream at the same time, regardless when the compounds are actually administered, including simultaneously. In many instances, the co-administration of the present compounds with traditional anticancer agents produces a synergistic (i.e., more than additive) result which is unexpected. In another embodiment, the compounds according to the present invention are given either simultaneously or sequentially with antibodies (conjugated or unconjugated), viruses, or bacteria. The antibodies, viruses, or bacteria could carry enzymes or gene encoding enzymes that activate the compounds described in the present invention. The enzymes include but not limit to NR, CPG2 and CPA.
- In another aspect of the present invention, the present compositions may be used to treat tumors and/or cancer which are resistant to one or more traditional anti-tumor/anti-cancer agents, such as those which have been described hereinabove. In this aspect of the invention, an effective amount of a composition is administered to a patient suffering from a drug-resistant tumor or cancer in order to treat the tumor or cancer. In this aspect of the present invention, the present compositions may be administered alone or in combination with other effective anti-tumor/anti-cancer agents.
- While not being limited by way of theory, it is believed that the compounds according to the present invention primarily induce their therapeutic effect in treating malignant tumors by functional as combined chloroethylating and carbamoylating agents.
- Having generally described the invention, reference is now made to the following specific examples that are intended to illustrate preferred and other embodiments and comparisons. The included examples are not to be construed as limiting the scope of this invention as is more broadly set forth above and in the appended claims. Other compounds not specifically presented in the examples section of this application may be readily synthesized following analogous methodologies and/or facile syntheses that are presented and known in the art. One of ordinary skill may readily synthesize all compounds set forth and described without engaging in undue experimentation by simply following the detailed synthetic methodology directly or adapting/modifying such synthetic methodology using techniques well known in the art.
- All reagents were purchased at commercial quality and used without further purification, and solvents were dried and/or distilled before use where necessary. All NMR spectra (1H, 13C and 31P) were determined on a Bruker AC300 spectrometer. Chemical shifts are measured in parts per million (ppm) relative to tetramethylsilane. Coupling constants are reported in Hertz (Hz). Flash column chromatography (FCC) was performed with Merck silica gel 60 (230-400 mesh), and reserved phase column chromatography (RPCC) was packed with CAT gel (Water, preparative C-18, 125 Å, 55-105 μm) eluting with milli-Q de-ionized water. Electrospray mass (ESMS) analyses were conducted on Q-Tof manufactured by Micromass (Manchester, UK) at Keck Laboratory of Yale University and the mass accuracy could be <0.02%.
- General procedure. To a solution of the appropriately substituted phenol (10.0 g) in TFA (100 mL) was added HMTA (1.1 equivalent) in small portions. The reaction solution was heated at reflux overnight. After cooling, the solution was treated with 50% H2SO4 solution (40 mL) for 4 h at room temperature, and then was extracted with ether (3×100 mL). The combined ether phases were washed with 5 M HCl solution and water, and then dried over anhydrous MgSO4. After filtration, the filtrate was evaporated and purified.
- 2-Hydroxy-5-trifluoromethyl-benzaldehyde (27a). Following the general procedure and FCC purification with 30% ethyl acetate-hexane, 4-trifluoromethyl phenol (10.0 g, 61.7 mmol) gave 2-hydroxy-5-trifluoromethyl-benzaldehyde 27 (3.9 g, 34%) as a pink solid.
- Rf (20% ethyl acetate-hexane): 0.47.
- 1H NMR (300 MHz, CDCl3) δ 11.31 (s, 1H, OH), 9.96 (s, 1H, CHO), 7.87 (d, J=1.6 Hz, 1H, C6-H (Ph)), 7.76 (dd, J=2.0 and 8.5 Hz, 1H, C4-H (Ph)) and 7.11 (d, J=8.8 Hz, 1H, C3-H (Ph)).
- 13CNMR (75 MHz, CDCl3) δ 195.8, 163.8, 133.4 (d), 131.0 (d), 125.3, 122.1 (m), 119.8 and 118.6.
- 4,5-Dichloro-2-hydroxy-benzaldehyde (27b) and 5,6-dichloro-2-hydroxy-benzaldehyde (28). Following the general procedure and FCC purification with 5-10% ethyl acetate-hexane, 3,4-dichlorophenol (10.0 g, 61.1 mmol) gave 5,6-dichloro-2-hydroxy-benzaldehyde 28 (2.2 g, 19%) as a light yellow solid.
- Rf (40% ethyl acetate-hexane): 0.63.
- 1H NMR (300 MHz, CDCl3) δ 11.98 (s, 1H, OH), 10.44 (s, 1H, CHO), 7.55 (d, J=9.4 Hz, 1H, C4-H (Ph)) and 6.89 (d, J=9.3 Hz, 1H, C3-H (Ph)).
- 13C NMR (75 MHz, CDCl3) δ 195.4, 162.4, 137.8 (2C), 135.6, 123.8 and 118.1. From the same reaction continuous FCC purification with 10% ethyl acetate-hexane gave 4,5-dichloro-2-hydroxy-benzaldehyde 27b (1.8 g, 15%) as a light yellow solid.
- Rf (40% ethyl acetate-hexane): 0.47.
- 1H NMR (300 MHz, CDCl3) δ 10.97 (s, 1H, OH), 9.84 (s, 1H, CHO), 7.64 (s, 1H, C3-H (Ph)) and 7.15 (s, 1H, C6-H (Ph)).
- 13C NMR (75 MHz, CDCl3) δ 194.7, 160.0, 149.9, 141.5, 134.0, 123.6 and 119.9.
- General procedure. To a stirred ice-cold solution of the appropriately substituted aldehyde (10.0 g) in acetonitrile (120 mL) was added diethyl chlorophosphate (1.1 equivalent) and TEA (I 0.1 equivalent). The reaction mixture was kept at room temperature overnight. After removal of the precipitate by filtration, the filtrate was evaporated and dried. The crude diethylphosphonoxy-benzaldehyde could be used without further purification.
- 4-Diethylphosphonoxy-benzaldehyde (23). Following the general procedure, 4-hydroxybenzaldehyde (9.0 g, 73.8 mmol) was converted to 4-diethylphosphonoxy-benzaldehyde 23 (18.9 g, 99%) isolated as a light yellow oil.
- 1H NMR (300 MHz, CDCl3) δ 9.98 (s, 1H, CHO), 7.91 (d, J=9.0 Hz, 2H, C3-H (Ph)), 7.39 (d, J=8.4 Hz, 2H, C2-H (Ph)), 4.26 (m, 4H, CH2) and 1.38 (t, J=6.9 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 190.5, 155.2 (d), 133.0, 131.4, 120.3 (d), 64.7 (d) and 15.8 (d).
- 31P NMR (121 MHz, CDCl3) δ 4.6.
- TOF ESMS calculated for (M+H)=259.07, observed 259.10.
- 2-Diethylphosphonoxy-benzaldehyde (24a). Following the general procedure, salicylaldehyde (9.0 g, 73.8 mmol) gave 24a (18.9 g, 99%) as a colorless oil.
- 1H NMR (300 MHz, CDCl3) δ 10.42 (s, 1H, CHO), 7.90 (d, J=7.7 Hz, 1H, C3-H (Ph)), 7.61 (t, J=8.0 Hz, 1H, C5-H (Ph)), 7.48 (d, J=8.7 Hz, 1H, C6-H (Ph)), 7.31 (t, J=7.1 Hz, 1H, C4-H (Ph)), 4.27 (m, 4H, CH2) and 1.37 (t, J=7.1 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 188.2, 152.5 (d), 135.5, 128.5, 127.1 (d), 125.2, 120.9 (d), 64.9 (d) and 15.8 (d).
- 31P NMR (121 MHz, CDCl3) δ 5.0.
- TOF ESMS calculated for (M+H)=259.07, observed 259.07.
- 5-Chloro-2-diethylphosphonoxy-benzaldehyde (24b). Following the general procedure, 5-chlorosalicylaldehyde (10.0 g, 73.8 mmol) gave 24b (19.4 g, 90%) as a colorless oil.
- 1H NMR (300 MHz, CDCl3) 610.34 (s, 1H, CHO), 7.84 (d, J=2.5 Hz, 1H, C3-H (Ph)), 7.55 (dd, J=8.8 and 2.5 Hz, 1H, C5-H (Ph)), 7.45 (d, J=8.8 Hz, 1H, C6-H (Ph)), 4.27 (m, 4H, CH2) and 1.38 (t, J=6.8 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 187.0, 151.1 (d), 135.2, 131.2, 128.2 (d), 128.1, 122.6 (d), 65.2 (d) and 16.0 (d).
- 31P NMR (121 MHz, CDCl3) δ 5.1.
- TOF ESMS calculated for (M+H)=293.03, observed 293.04.
- 5-Chloro-2-hydroxymethyl-phenol (25). A solution of 4-chloro salicylic acid (10.0 g, 58.0 mmol) in THF (150 mL) was treated with LAH (1.5 equivalent) at reflux for 2 h. After cooling to ambient temperature, the reaction solution was quenched by 1 N NaHSO4 solution (200 mL), and then extracted with ether (300 mL). After separation, the organic layer was dried over anhydrous MgSO4, filtered and concentrated. The dried crude product 25 (7.5 g, 81%) was obtained as a gray solid, and was pure enough for use without further purification.
- 1H NMR (300 MHz, DMSO-d6) δ 9.85 (s, 1H, Ph-OH), 7.27 (d, J=8.2 Hz, 1H, C3-H (Ph)), 6.81 (d, J=8.2 Hz, 1H, C4-H (Ph)), 6.78 (s, 1H, C6-H (Ph)), 5.03 (m, 1H, OH) and 4.41 (d, J=4.1 Hz, 2H, PhCH2).
- 13C NMR (75 MHz, DMSO-d6) 8155.0, 131.0, 128.6, 128.0, 118.5, 114.2 and 57.7.
- 4-Chloro-2-diethylphosphonoxy-benzyl alcohol (26). A solution of 25 (8.6 g, 54.8 mmol), DIEA (2.1 equivalent) and DMAP (0.1 equivalent) in acetonitrile (200 mL) was placed in −20° C. bath. To the above cold solution was added CC14 (5.0 equivalent) and diethyl phosphite (1.1 equivalent). The reaction solution was kept for 2 h at room temperature. The solvent was rotary evaporated, and the crude oil was purified by FCC with 60% ethyl acetate-hexane to obtain 26 (10.9 g, 68%) as a light yellow oil.
- Rf (80% ethyl acetate-hexane): 0.34.
- 1H NMR (300 MHz, CDCl3) δ 7.40 (d, J=8.2 Hz, 1H, C3-H (Ph)), 7.23 (s, 1H, C6-H (Ph)), 7.19 (d, J=8.5 Hz, 1H, C4-H (Ph)), 4.62 (s, 2H, PhCH2), 4.24 (m, 4H, CH2) and 1.37 (t, J=7.4 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 148.2 (d), 133.6 (d), 131.6 (d), 131.0, 125.8, 120.9 (d), 65.1 (d), 59.1 and 15.9 (d).
- 31P NMR (121 MHz, CDCl3) δ 6.0.
- 4-Chloro-2-diethylphosphonoxy-benzaldehyde (24c). To a stirred solution of 26 (10.7 g, 36.3 mmol) in dichloromethane (600 mL) was added PCC in small portions over 30 min at room temperature. The reaction was monitored by TLC. Then, the reaction mixture was passed through a Celite Filter pad, and the filtrate was rotary evaporated. The residual oil was purified by a silica gel pad eluting with ethyl acetate to obtain 24d (9.5 g, 90%) as a green oil.
- 1H NMR (300 MHz, CDCl3) δ 10.34 (s, 1H, CHO), 7.84 (s, 1H, C3-H (Ph)), 7.52 (s, 1H, C6-H (Ph)), 7.29 (s, 1H, C4-H (Ph)), 4.29 (in, 4H, CH2) and 1.39 (s, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 186.8, 152.4 (d), 140.9, 129.3, 125.4 (d), 125.3, 121.1, 64.9 (d) and 15.6 (d).
- 31P NMR (121 MHz, CDCl3) δ 4.8.
- TOF ESMS calculated for (M+H)=293.03, observed 293.06.
- General Procedure. To a solution of the corresponding diethylphosphonoxy-benzaldehyde (23 or 24a-c, 10 mmol) in dichloromethane (10 mL) was added methylamine (2 N in THF, 2.0 equivalent). The reaction solution was kept at room temperature overnight, filtered through a silica gel pad, the filtrate was rotary evaporated and dried in vacuum. The resulting crude oil was dissolved in methanol (50 mL). To the above solution was added NaBH4 (2.0 equivalent) in small portions at 0° C., and the solution was kept stirring continuously for 4 h. After evaporation, the residue was distributed in water (50 mL) and dichloromethane (50 mL). The aqueous phase was separated and extracted with dichloromethane (50 mL) once. The combined organic phases were dried over anhydrous MgSO4, filtered and evaporated. The crude N-(diethylphosphonoxybenzyl)-N-methylamines (15 or 16a-c) was pure enough for use without further purification.
- N-(4-Diethylpho sphonoxybenzyl)-N-methyl amine (15). Following the general procedure, 23 (29.9 g, 116 mmol) gave 15 (22.3 g, 71%) as a yellow oil.
- 1H NMR (300 MHz, CDCl3) δ 7.31 (d, J=8.0 Hz, 2H, C3-H (Ph)), 7.17 (d, J=8.5 Hz, 2H, C2-H (Ph)), 4.21 (m, 4H, CH2), 3.73 (s, 2H, PhCH2), 2.42 (s, 3H, NCH3) and 1.34 (t, J=6.9 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 149.4 (d), 135.6, 129.3, 119.5 (d), 64.2 (d), 54.5, 35.1 and 15.7 (d).
- 31P NMR (121 MHz, CDCl3) δ 5.3.
- TOF ESMS calculated for (M+H)=274.11, observed 274.11.
- N-(2-Diethylphosphonoxybenzyl)-N-methyl amine (16a). Following the general procedure, 24a (19.0 g, 73.6 mmol) gave 16a (16.4 g, 82%) as a light yellow oil.
- 1H NMR (300 MHz, CDCl3) δ 7.37 (d, J=7.4 Hz, 1H, C3-H (Ph)), 7.33 (d, J=7.9 Hz, 1H, C6-H (Ph)), 7.24 (t, J=7.2 Hz, 1H, C5-H (Ph)), 7.14 (t, J=7.3 Hz, 1H, C4-H (Ph)), 4.22 (m, 4H, CH2), 3.82 (s, 2H, PhCH2), 2.44 (s, 3H, NCH3) and 1.35 (t, J=7.0 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 148.6 (d), 130.5 (d), 130.2, 128.1, 124.8, 119.7, 64.4 (d), 49.9, 35.5 and 15.8 (d).
- 31P NMR (121 MHz, CDCl3) δ 5.6.
- TOF ESMS calculated for (M+H)=274.11, observed 274.13.
- N-(4-Chloro-2-diethylphosphonoxybenzyl)-N-methyl amine (16b). Following the general procedure, 24b (21.9 g, 74.9 mmol) gave 16b (18.3 g, 80%) as a light yellow oil.
- 1H NMR (300 MHz, CDCl3) δ 7.39 (d, J=2.2 Hz, 1H, C3-H (Ph)), 7.27 (d, J=7.9 Hz, 1H, C6-H (Ph)), 7.20 (dd, J=8.3 and 2.6 Hz, 1H, C5-H (Ph)), 4.23 (m, 4H, CH2), 3.78 (s, 2H, PhCH2), 2.45 (s, 3H, NCH3) and 1.36 (t, J=7.0 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 147.1 (d), 132.8 (d), 130.1 (d), 129.7, 127.7, 121.1, 64.6 (d), 49.6, 35.6 and 15.9 (d).
- 31P NMR (121 MHz, CDCl3) δ 5.6.
- TOF ESMS calculated for (M+H)=308.07, observed 308.08.
- N-(5-Chloro-2-diethylphosphonoxybenzyl)-N-methyl amine (16c). Following the general procedure, 24c (23.9 g, 81.7 mmol) gave 16c (18.9 g, 76%) as a light yellow oil.
- 1H NMR (300 MHz, CDCl3) δ 7.35 (s, 1H, C6-H (Ph)), 7.30 (d, J=10.4 Hz, 1H, C3-H (Ph)), 7.14 (d, J=8.4 Hz, 1H, C4-H (Ph)), 4.24 (m, 4H, CH2), 3.78 (s, 2H, PhCH2), 2.43 (s, 3H, NCH3) and 1.37 (t, J=6.8 Hz, 6H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 140.9 (d), 133.0, 131.0, 129.4 (d), 125.1, 120.3 (d), 64.7 (d), 49.4, 35.5 and 15.9 (d).
- 31P NMR (121 MHz, CDCl3) δ 5.4.
- TOF ESMS calculated for (M+H)=308.07, observed 308.08.
- General Procedure. To a cold stirred solution of 90CE (10 mmol) in acetonitrile (40 mL) was added phosgene (20% in toluene, 1.0 equivalent) and DIEA (1.0 equivalent). The reaction solution was kept at 0° C. for 20 min. Then, to the above solution was added a solution of the corresponding N-(diethylphosphonoxy-benzyl)-N-methylamine (15 or 16a-c, 10 mmol) in dichloromethane (5 mL) and DIEA (another 1.0 equivalent). The final reaction solution was kept at 5° C. overnight. After evaporation, the residue was distributed in water (80 mL) and dichloromethane (80 mL). The aqueous phase was separated and extracted with dichloromethane (80 mL) twice. The combined organic phases were dried over anhydrous MgSO4, filtered and evaporated. The crude protected phosphates (17 or 18a-c) were obtained as oils.
- A solution of the respective diethyl-protected phosphate (17 or 18a-c, 10 mmol) in dichloromethane (60 mL) was treated with excess TMSBr (40 mL) at 5° C. overnight. After evaporation and drying in vacuum, the crude free phosphoric acid (19 or 20a-c) was obtained as a glassy solid.
- To the crude compound (19 or 20a, 10 mmol) was added water (about 30 mL). The suspension was stirred for 2 h at ambient temperature, and then a minimum amount of water was added to complete dissolution. The aqueous solution was purified by RPCC with de-ionized water. The fractions were monitored by 31P NMR and combined. After lyophylization, the purified free phosphoric acid (19 or 20a) was obtained as a white powder.
- 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazine (90CE). Following a published procedure (Shyam, et al. J Med Chem. 1987, 30: 2157), the reaction of 2-hydroxyethyl-hydrazine and methanesulfonyl chloride in the presence of pyridine as a base provided the mesylate, which subsequently reacted with lithium chloride to result in 90CE. 90CE was obtained as a white solid after purification by FCC with 5% methanol in dichloromethane.
- Rf (50% ethyl acetate-hexane): 0.30.
- 1H NMR (300 MHz, CDCl3) δ 6.82 (s, 1H, NH), 3.99 (t, J=6.8 Hz, 2H, ClCH2), 3.86 (t, J=5.6 Hz, 2H, NCH2), 3.19 (s, 3H, SCH3) and 3.13 (s, 3H, SCH3).
- 13C NMR (75 MHz, CDCl3) δ 54.0, 41.0, 40.2 and 38.4.
- Phosphoric acid mono-{4-{N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl}-phenyl} ester (19). Following the general procedure, 15 (15.4 g, 56.8 mmol) and 90CE (14.2 g, 1.0 equivalent) gave phosphoric acid 4-{N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl-phenyl ester diethyl ester (17, 25.2 g, 80%). Compound 17 (11.0 g, 20.1 mmol) was converted to 19 (3.8 g, 38%) as a white powder.
- 1H NMR (300 MHz, D2O) δ 7.11 (d, J=8.1 Hz, 2H, C3-H (Ph)), 6.95 (d, J=7.5 Hz, 2H, C2-H (Ph)), 4.36 (m, 2H, PhCH2), 3.89 (m, 2H, ClCH2), 3.67 (m, 2H, NCH2), 3.23 (s, 3H, NCH3), 2.92 (s, 3H, SCH3) and 2.87 (s, 3H, SCH3).
- 13C NMR (75 MHz, D2O) δ 156.6, 153.8 (d), 133.4, 132.0, 123.0 (d), 57.3, 55.7, 43.6, 42.0, 40.4 and 39.1.
- 31P NMR (121 MHz, D2O)
δ 9. - TOF ESMS calculated for (M+H)=494.01, observed 493.98.
- Phosphoric acid mono-{2-{N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl}-phenyl} ester (20a). Following the general procedure, 16a (16.4 g, 60.5 mmol) and 90CE (15.1 g, 1.0 equivalent) gave phosphoric acid 2-{N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl}-phenyl ester diethyl ester (18a, 29.7 g, 89%). Compound 18a (10.5 g, 19.2 mmol) gave 20a (2.6 g, 27%) as a white powder.
- 1H NMR (300 MHz, D2O) δ 7.1-7.2 (m, 3H, C3-H, C5-H and C6-H (Ph)), 6.94 (m, 1H, C4-H (Ph)), 4.45 (m, 2H, PhCH2), 3.84 (m, 2H, ClCH2), 3.64 (m, 2H, NCH2), 3.20 (s, 31H, NCH3), 2.93 (s, 3H, SCH3) and 2.92 (s, 3H, SCH3).
- 13C NMR (75 MHz, D2O) δ 156.8, 152.5 (d), 131.8, 131.7, 128.7 (d), 126.7, 122.5, 57.2, 51.4, 43.5, 42.1, 40.5 and 39.9.
- 31P NMR (121 MHz, D2O) δ 9.8.
- TOF ESMS calculated for (M+H)=494.01, observed 494.00.
- General Procedure. The corresponding crude phosphoric acid (19 or 20a-c, 10 mmol) was neutralized with an aqueous saturated sodium bicarbonate (NaHCO3) solution (100 mL). The suspension was stirred for 2 h at ambient temperature, and then added to a minimum amount of water to make homogenous. The aqueous solution was purified by RPCC with de-ionized water. The fractions were monitored by 31P NMR and combined. After lyophylization, the corresponding disodium salt (21 or 22a-c) was obtained as a white powder.
- Phosphoric acid 4-{N-11,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl}-phenyl ester disodium salt (21). Following the general procedure, crude 19 (9.5 g, 19.3 mmol) gave 21 (5.6 g, 54%) as a white powder.
- 1H NMR (300 MHz, D2O) δ 7.08 (d, J=8.3 Hz, 2H, C3-H (Ph)), 6.97 (d, J=8.1 Hz, 2H, C2-H (Ph)), 4.38 (m, 2H, PhCH2), 3.92 (m, 2H, ClCH2), 3.71 (m, 2H, NCH2), 3.26 (s, 3H, NCH3), 2.95 (s, 3H, SCH3) and 2.89 (s, 3H, SCH3).
- 13C NMR (75 MHz, D2O) δ 156.5, 156.1 (d), 131.7, 131.4, 122.9 (d), 57.4, 55.8, 43.7, 42.0, 40.5 and 39.0. 31P NMR (121 MHz, D2O) δ 14.2.
- TOF ESMS calculated for (M−H)=492.01, observed 492.10.
- Phosphoric acid 2-{N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl}-phenyl ester disodium salt (22a). Following the general procedure, crude 20a (8.8 g, 17.8 mmol) gave 22a (5.7 g, 59%) as a white powder.
- 1H NMR (300 MHz, D2O) δ 7.21 (d, J=8.4 Hz, 1H, C3-H (Ph)), 7.0-7.2 (m, 2H, C5-H and C6-H (Ph)), 6.86 (t, J=7.2 Hz, 1H, C4-H (Ph)), 4.52 (m, 2H, PhCH2), 3.90 (m, 2H, ClCH2), 3.68 (m, 2H, NCH2), 3.27 (s, 3H, NCH3), 2.97 (s, 3H, SCH3) and 2.93 (s, 3H, SCH3).
- 13C NMR (75 MHz, D2O) δ 156.7, 154.6 (d), 131.3, 130.9, 128.3 (d), 124.7, 122.4, 57.3, 51.4, 43.6, 42.0, 40.5 and 39.9.
- 31P NMR (121 MHz, D2O) 614.1.
- TOF ESMS calculated for (M−H)=492.01, observed 492.05.
- Phosphoric acid 2-{N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinylcarbonyl]-N-methylaminomethyl}-4-chloro-phenyl ester disodium salt (22b). Following the general procedure, crude 20b (14.5 g, 27.6 mmol) gave 22b (8.3 g, 53%) as a white powder.
- 1H NMR (300 MHz, D2O) δ7.26 (s, 1H, C3-H (Ph)), 7.17 (m, 1H, C5-H (Ph)), 7.08 (d, J=7.2 Hz, 1H, C6-H (Ph)), 4.48 (m, 2H, PhCH2), 3.93 (m, 2H, ClCH2), 3.72 (m, 2H, NCH2), 3.30 (s, 3H, NCH3), 3.03 (s, 3H, SCH3) and 3.01 (s, 3H, SCH3).
- 13C NMR (75 MHz, D2O) δ 156.8, 153.3 (d), 134.6, 130.8, 128.9, 126.7, 123.6, 57.3, 51.3, 43.6, 42.1, 40.6 and 40.1.
- 31P NMR (121 MHz, D2O) 614.2.
- TOF ESMS calculated for (M−H)=525.96, observed 525.93.
- Phosphoric acid 2-{N-[1,2-bis(methylsulfonyl)-2-(2-chloroethyl)-hydrazinyl-carbonyl]-N-methylaminomethyl}-5-chloro-phenyl ester disodium salt (22c). Following the general procedure, crude 20c (16.2 g, 30.8 mmol) gave 22c (8.9 g, 51%) as a white powder.
- 1H NMR (300 MHz, D2O) δ 7.28 (s, 1H, C6-H (Ph)), 7.03 (d, J=8.4 Hz, 1H, C3-H (Ph)), 6.87 (d, J=8.2 Hz, 1H, C4-H (Ph)), 4.47 (m, 2H, PhCH2), 3.91 (m, 2H, ClCH2), 3.70 (m, 2H, NCH2), 3.26 (s, 3H, NCH3), 3.00 (s, 3H, SCH3) and 2.96 (s, 3H, SCH3).
- 13C NMR (75 MHz, D2O) 6156.7, 155.3 (d), 135.6, 132.0, 127.0 (d), 124.5, 122.4, 57.3, 51.0, 43.7, 42.0, 40.5 and 40.0.
- 31P NMR (121 MHz, D2O) 614.1.
- TOF ESMS calculated for (M−H)=525.96, observed 526.01.
- 4-Formylphenyloxycarbonyl-glutamic acid di-tert-butyl ester (40). To a cold stirred solution of 4-hydroxybenzyl alcohol (2.0 g, 16.9 mmol) in acetonitrile (50 mL) and dichloromethane (50 mL) was added phosgene (20% in toluene, 1.0 equivalent) and DIEA (1.0 equivalent). The reaction solution was kept at 0° C. for 30 min. Next, to the above solution was added a solution of glutamic acid di-tert-butyl ester 39 (1.0 equivalent) in dichloromethane (50 mL) including DIEA (2.0 equivalent). The reaction mixture was kept at 0° C. overnight. Then, the mixture was treated with 0.5 N KHSO4 solution (50 mL). After separation, the organic phase was washed with brine (80 mL), dried over anhydrous MgSO4, rotary evaporated and dried in vacuum. The crude carbamate 40 (6.7 g, 97%) was obtained as a light yellow semi-solid.
- 1H NMR (300 MHz, CDCl3) δ 9.97 (s, 1H, CHO), 7.89 (d, J=8.1 Hz, 2H, C3-H (Ph)), 7.32 (d, J=8.7 Hz, 2H, C2-H (Ph)), 5.91 (d, J=7.8 Hz, 1H, NH), 4.32 (m, 1H, C1H), 2.35 (m, 2H, C2H), 2.00 (m, 2H, C3H), 1.50 and 1.46 (s, 2×9H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 191.0, 172.1, 170.6, 155.6, 153.1, 133.4, 131.1, 121.9, 82.7, 80.9, 54.1, 31.4, 28.0, 27.9 and 27.5.
- TOF ESMS calculated for (M+H)=408.20, observed 408.19.
- 4-(Methyaminomethyl)phenyloxycarbonyl-glutamic acid di-tert-butyl ester (41). A stirred solution of 40 (6.1 g, 14.9 mmol) in dichloromethane (50 mL) was treated with 2 N methylamine-THF solution (10 mL) at 0° C. overnight. After removal of solvents, the residual oil was dissolved in methanol (80 mL) and placed in an ice-bath. To the above solution was added sodium borohydride in small portions over 30 min. The reaction solution was kept at 0° C. for 1 hour, and solvent was then evaporated. The residue was worked up with brine and dichloromethane. After separation, the organic phase was dried over anhydrous MgSO4, rotary evaporated and dried in vacuum. The crude amine 41 (5.4 g, 78%) was obtained as a light yellow glassy solid.
- 1H NMR (300 MHz, CDCl3) δ 7.04 (d, J=8.3 Hz, 2H, C3-H (Ph)), 6.78 (d, J=8.1 Hz, 2H, C2-H (Ph)), 5.36 (d, J=7.4 Hz, 1H, CONH), 4.39 (m, 1H, C1H), 2.86 (d, J=4.6 Hz, 3H, NCH3), 2.74 (d, J=4.8 Hz, 2H, NCH2), 2.34 (m, 2H, C2H), 1.92 (m, 2H, C3H), 1.49 and 1.42 (s, 2×9H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 172.6, 172.4, 157.9, 156.1, 128.6, 128.3, 115.6, 82.0, 80.7, 53.9, 51.5, 33.8, 31.6, 28.0, 27.9 and 27.6.
- TOF ESMS calculated for (M+H)=423.25, observed 423.24.
- 4-{N-(1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)hydrazin-2-yl-carbonayl)-N-methyaminomethyl}phenyloxycarbonyl-glutamic acid di-tert-butyl ester (42). To a cold stirred solution of 90CE (1.5 g, 5.9 mmol) in acetonitrile (30 mL) was added phosgene (20% in toluene, 1.0 equivalent) and DIEA (1.0 equivalent). The reaction solution was kept at 0° C. for 30 min. Then, to the above solution was added a solution of 41 (1.0 equivalent) in acetonitrile (30 mL) including DIEA (1.0 equivalent). The reaction mixture was kept at 0° C. overnight. After evaporation of solvent, the resulting residue was worked up with water and dichloromethane. After separation, the organic phase was dried over anhydrous MgSO4, rotary evaporated and dried in vacuum. The crude N-benzyl-N-methylaminocarbonyl-hydrazine 42 (3.6 g, 87%) was obtained as a light yellow glassy solid.
- 1H NMR (300 MHz, CDCl3) δ 7.31 (d, J=8.0 Hz, 2H, C3-H (Ph)), 7.21 (d, J=8.2 Hz, 2H, C2-H (Ph)), 5.38 (d, J=7.5 Hz, 1H, CONH), 4.52 (bs, 1H, C1H), 3.82 (m, 2H, ClCH2), 3.67 (m, 2H, NCH2), 3.55 (s, 3H, NCH3), 3.23 and 3.14 (s, 2×3H, SO2CH3), 2.87 (s, 2H, NCH2Ph), 2.35 (m, 2H, C2H), 1.98 (m, 2H, C3H), 1.47 and 1.43 (s, 2×9H, CH3).
- 13C NMR (75 MHz, CDCl3) δ 172.7, 172.1, 157.6, 148.8, 137.0, 128.9, 128.7, 121.0, 81.7, 80.5, 53.8, 53.4, 51.2, 41.9, 41.7, 41.3, 40.4, 31.5, 27.9, 27.8 and 27.4.
- TOF ESMS calculated for (M+H)=699.21, observed 699.18.
- 4-{N-(1,2-Bis(metliylsulfonyl)-1-(2-chloroethyl)hydrazin-2-yl-carbonayl)-N-methyaminomethyl}plienyloxycarbonyl-glutaniic acid (42) and its disodium salt (44). The crude glassy solid 42 (4.4 g, 6.4 mmol) was treated with formic acid (200 mL) at 5° C. overnight. After frozen at −78° C., the desired
glutamic acid 43 was obtained by lyophylization as sticky white solid. - Without further purification, crude 43 was treated with saturated NaHCO3 solution (200 mL) at room temperature for 2 hours. The resulting milky mixture was purified by RPFCC with de-ionized water. The fractions were monitored by HPLC and combined. After lyophylization, the disodium salt 44 (0.78 g, 20%) was obtained as a white powder.
- 1H NMR (300 MHz, D2O) δ 7.15 (d, J=8.0 Hz, 2H, C3-H (Ph)), 7.08 (d, J=7.8 Hz, 2H, C2-H (Ph)), 4.31 (bs, 1H, C1H), 3.83 (m, 2H, ClCH2), 3.67 (m, 2H, NCH2), 3.46 (s, 3H, NCH3), 3.16 (s, 3H, SO2CH3), 2.95 (m, 2H, NCH2Ph), 2.70 (s, 3H, SO2CH3), 1.99 (m, 2H, C2H) and 1.75 (m, 2H, C3H).
- 13C NMR (75 MHz, D2O) δ 185.0, 182.7, 162.0, 154.4, 150.8, 140.0, 131.0, 123.6, 59.1, 55.1, 53.5, 43.7, 42.9, 36.7, 36.4 and 31.2.
- TOF ESMS calculated for (M+H)=631.05, observed 631.04, and for (M+Na)=653.03, observed 653.03.
- Determination of Solubility and Stability in Aqueous Solutions
- The solubility of VNP40101M in water is 0.66 mg/mL at room temperature (Krishna, et al. AAPS PharrnsciTech 2001, 2: article 14). The solubility of the newly synthesized SHPs (19, 20a, 21, and 22a) is much higher than that of VNP40101M, as shown in Table 1.
- For the free
phosphoric acid 19 and 20a, an excess amount of the drug was placed in a glass vial containing 2.0 mL of water. The vials were shaken in a Glas Col rotary apparatus at room temperature for 24 hours. The suspension containing undissolved drug was centrifuged; the supernatant was carefully separated and analyzed by HPLC for drug concentration. The solubility of 19 and −20a was found to be 293 and 46 mg/mL respectively. Aqueous solutions of 19 and 20a were colorless. Similarly, the solubility of thesodium salts 21 and 22a was determined visually by adding incremental quantities of the drug to 2.0 mL of water in a glass vial. The vials were shaken at room temperature in a Glas Col rotary apparatus until the drug dissolved entirely. Additional fixed quantities of drug were added and the vials shaken until complete dissolution. This process was continued until no more drug dissolved.Compounds 21 and 22a are highly water-soluble. Because of limited drug supplies determination of the solubilities at equilibrium could not be obtained. Solubilities of >0.98 and >1.35 g/mL for 21 and 22a, respectively, were determined.TABLE 1 Water-solubility of the Projected SHPs at Room Temperature Compound Water-solubility, mg/mL VNP40101M 0.66 PAP-101M (19) 293 OAP-101M (20a) 46 PAP-Na-101M (21) >980 OAP-Na-101M (22a) >1350 - The stabilities of PAP-101M (19), OAP-101M (20a), and VNP40101M were investigated in potassium phosphate buffers (50 mM) at
pH TABLE 2 Aqueous Stability of the Projected SHPs Half- life Compound pH 3 pH 5pH 7pH 9VNP40101M No 118 day 12.2 hr 6.9 min hydrolysis PAP-101M (19) No No No No hydrolysis hydrolysis hydrolysis hydrolysis OAP-101M (20a) No No No 171 day hydrolysis hydrolysis hydrolysis
concentration of the respective drug. The first-order kinetic half-lives of each drug were calculated. As demonstrated in Table 2 below, the results indicate clearly that the phosphate-bearing prodrugs (19 and 20a) were quite stable compared to VNP40101M. - Table 3 shows the bioconversion of
compounds 19 and 20a in the presence of AP (from bovine intestinal mucosa, Sigma) or human plasma. Each drug, at a final concentration of approximately 50 μg/mL, was incubated at 37° C. in 50 mM Tris buffered saline (pH 7.6) containing approximately 0.055 unit/mL of the phosphatase enzyme.TABLE 3 In vitro Enzymatic Bioconversion and Human Plasma Stability Half-life, min Alkaline Buffered saline phosphatase Human plasma pH 7.6 Compound 37° C. 37° C. 37° C. VNP40101M Not tested 14.5 20.5 PAP-101M (19) 21.1 34.3 No hydrolysis OAP-101M (20a) 29.0 53.3 No hydrolysis - A control sample of each drug at a final concentration of 50 μg/mL in 50 mM Tris buffered saline (pH 7.6) without AP was also incubated at 37° C. Aliquots of each solution were taken periodically; disappearance of the tested drug was determined by HPLC.
- The stability of
compounds 19, 20a and VNP40101M was evaluated in 100% human plasma (pooled mixed gender, BioChemed) at a final concentration of 50 μg/mL. Each drug (19 or 20a) was incubated in human plasma at 37° C. for a maximum of two hours. Aliquots of the incubation mixture were taken at various time points and extracted with acetonitrile. The extract was separated by centrifugation and analyzed directly by HPLC. In a similar manner, VNP40101M was incubated in human plasma at 37° C. for a maximum of one hour. At various time points, aliquots of the incubation mixture were removed and extracted with 0.5% H3PO4 in acetonitrile. The extract was separated by centrifugation and analyzed directly by HPLC. For comparison, the stability of each drug incubated in 50 mM Tris buffered saline (pH 7.6) instead of 100% human plasma was also determined. - It is clearly shown that (a) the projected
prodrugs 19 and 20a were more stable in buffered saline and human plasma than VNP40101M; and (b) they could be rapidly activated by alkaline phosphatase. OAP-101M (20a) was shown to have a longer half-life than PAP-101M (19). - Preliminary investigations of the pharmacokinetic profiles of
prodrugs 19 and 20a were conducted in female Sprague-Dawley rats (10 weeks old, 250 g, Charles River). Each prodrug was administered as a single bolus intravenous (iv) injection via the jugular vein at a dose of 50 mg per kg (mpk) of body weight. Blood samples were collected on the day of dosing at the following time points: pre-dose and approximately 2, 10, 30 min, 1, 2, and 24 hr, after dosing. At each time point, approximately 0.2 mL of blood was collected in a tube containing an anticoagulant (heparin), which was immediately acidified by adding 0.005 mL of a 2.0 M citric acid solution. Then, the tube was inverted 4 to 6 times and immediately placed on ice. The blood samples were centrifuged within 30 min after blood collection at 3,000 rpm for 10-20 min at 2-8° C., and the plasma fraction was transferred to a labeled Nunc cryovial. The plasma samples were immediately frozen on dry ice and stored at −20° C. until HPLC-UV analysis. Animals were euthanized with CO2 inhalation after experiments. - Bioanalytical methods were developed to quantify these prodrugs in rat plasma using HPLC-UV at either 220 nm or 230 nm. Each plasma sample (0.1 mL) was extracted with 0.2 mL of acetonitrile. The extract was separated by centrifugation and analyzed directly by HPLC-UV. HPLC calibration standards were prepared in control rat plasma and processed as above. The standard curve had a linear range of 1.0-50 μg/mL.
- Determination of 19 could not be done because of the fast conversion or clearance of the compound from the circulation of rats. As demonstrated in Table 4, pharmacokinetic parameters (area under the concentration-time curve-AUC, total body clearance—Cl, steady-state volume of distribution—Vss, maximum concentration—Cmax, and terminal half-life-T1/2) were calculated. Plasma half-life for 20a was approximately 14 min, which was longer than that of 19. Comparison to
VNP 101M (10 mpk ofradioactive VNP 101M was used in previous experiments) is difficult because of the difference in doses used in two the studies.TABLE 4 Pharmacokinetic Parameters of 19 and 20a in Rats AUC Cl (min*ug/ (mL/min/ Vss Cmax T1/2 Drug mL) kg) (mL/kg) (μg/mL) (min) 19 — — — — — 20a 1312.0 37.8 145.6 238.6 14.0 VNP40101M* 325.8 ± 2.0 ± 0.91 ± 11.3 ± 20.9 ± 113.8 0.6 0.16 2.1 8.7
*The plasma VNP40101M level (˜10 μg/mL) peaked at 2 min after administration of [14C]-VNP40101M. The VNP40101M levels declined, with a half-life of ˜20 min. After the first 2 hours, no VNP40101M could be detected in the plasma (see, Almassian, et al. Proceedings AACR, 2001, 42: 326, article 1756).
- The anti-tumor effects of VNP40101M and prodrugs, including PAP-101M (19), OAP-101M (20a), PAP-Na-101M (21), and OAP-Na-101M (22a), were evaluated in both the B16-F10 murine melanoma and HTB177 human lung carcinoma models. B16-FI0 melanoma cells were implanted subcutaneously (5×105 cells) into
C57BU 6 mice, which were randomized into groups of ten immediately after tumor cell implantation (Day 0). OnDay 2, mice were injected intraperitoneally with either a bolus injection of 0.1 mL PBS or drug. The treatment was carried out weekly for four consecutive weeks. Tumor measurement in three dimensions was determined once a week with the formula L×H×W/2, where L, H, and W represent length, height, and width, respectively. As shown inFIG. 11 , B16-F10 tumors in the PBS control group grew exponentially, reaching a size around 4,000 mm3 onDay 24. VNP40101M and tested prodrugs effectively inhibited the growth of B16-F 10 melanoma. OnDay 24, tumor growth was inhibited by 81% in mice treated with 80 mg/kg of VNP40101M, and by 75 to 91% in mice treated with equal molar doses of the prodrugs. Of all the prodrugs, OAP-101M (20a) and OAP-Na-101M (22a) were the most efficacious; tumor growth inhibitions were 91% and 89.5%, respectively. The inhibitions were significantly (p<0.05) higher than those in others groups. Tumor-bearing mice receiving OAP-101M (20a) also survived longer than that received other drugs (FIG. 12 ). The toxicity of these drugs in mice was mild as determined by body weight loss and animal appearance, as illustrated inFIG. 13 . The anti-tumor effects of these prodrugs had also been investigated in HTB177 human lung carcinoma implanted in nu/nu CD-1 mice, as demonstrated inFIGS. 14 and 15 , and been shown that OAP-101M (20a) and OAP-Na-101M (22a) holdout promise as well. - In short, we have shown that the water-soluble SHP prodrugs OAP-101M (20a) and OAP-Na-101M (22a) have anti-tumor activity against the B 16-F10 murine melanoma and HTB 177 human lung carcinoma and the efficacy was as good as or better than VNP40 μM.
- In summary, phosphate-bearing SHPs OAP-101M (20a) and OAP-Na-101M (22a) possesses the following characteristics: (a) highly water-soluble and stable in aqueous solution at
pH 3 to 9; (b) its conversion can be catalyzed by alkaline phosphatase (AP); (c) has longer half-life in saline and in human plasma than PAP-101M (19) and VNP40101M; (d) has better in vivo PK profiles than PAP-101M; (e) has good anti-tumor activities against B16-F10 murine melanoma and HTB177 human lung carcinoma in mice as compared to PAP-101M (19), PAP-Na-101M (21) and VNP40101M; and (f) its sodium salt (22a) has even a higher water-solubility and similar anti-tumor activity than the free acid 20a. - It is to be understood by those skilled in the art that the foregoing description and examples are illustrative of practicing the present invention, but are not in no way limiting. Variations of the detail presented herein may be made without departing from the spirit and scope of the present invention as defined by the following claims.
Claims (52)
1-22. (cancelled)
23. A pharmaceutical composition comprising an effective amount for treating non-tumorous cancer of a compound or its pharmaceutically acceptable salt according to the structure:
Where R is —CH3 or —CH2CH2Cl; R′ is C1-C7 alkyl or —CH2CH2Cl;
one of R2 or R4, but not both, is selected from OPO3H2, NO2, OCO(Glu), NHCO(Glu) and NHR7 and the other of R2 or R4 which is unassigned, and R3, R5 and R6, are, independently selected from H, F, Cl, Br, I, OH, OPO3H2, OCH3, CF3, OCF3, NO2, CN, SO2CH3, SO2CF3, COCH3, COOCH3, SCH3, SF5, NHR8, N(R9)2 and C1-C7 alkyl, with the proviso that at least two of R2, R3, R4, R5 and R6 are H; R7 is H, glutamyl or a polyglutamic acid polypeptide residue (—COCH(NHR7a)CH2CH2CO2H where R7a is glutamyl or a polyglutamic acid polypeptide residue having from 1 to 50 peptide linkages; R8 is H or C1-C7 alkyl;
and R9 is CH3 or CH2CH3; optionally, in combination with a pharmaceutically acceptable additive, carrier, or excipient.
24. The composition according to claim 23 wherein R is —CH2CH2Cl.
25. The composition according to claim 23 wherein said R′ is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl or substituted hexyl.
26. The composition according to claim 25 wherein R′ is methyl.
27. The composition according to claim 23 wherein R2 is OPO3H2 or its pharmaceutically acceptable salt.
28. The composition according to claim 23 wherein R4 is F, Cl or OCH3 when R3, R5 and R6 are each H.
29. The composition according to claim 23 wherein R5 is F, Cl, OCH3 or OCF3 when R3, R4 and R6 are each H.
30. The composition according to claim 23 two of R3, R4, R5 or R6 are independently F or Cl.
31. The composition according to claim 30 wherein R4 and R5 are independently F or Cl.
32. The composition according to claim 30 wherein R5 and R6 are independently F or Cl.
33. The composition according to claim 31 wherein R4 and R5 are Cl.
34. The composition according to claim 32 wherein R5 and R6 are Cl.
35. The composition according to claim 23 wherein R5 is OPO3H2 or its pharmaceutically acceptable salt.
36. The composition according to claim 23 wherein R2 is NO2 when R3, R4 and R6 are each H.
37. The composition according to claim 23 wherein R4 is NO2 and R2, R3 and R6 are each H.
38. The composition according to claim 23 wherein R4 is OCO(Glu) and R2, R3, R5 and R6 are each H.
39. The composition according to claim 38 wherein Glu is in the form of a pharmaceutically acceptable salt.
40. The composition according to claim 23 wherein R4 is NHCO(Glu) and R2, R3, R5 and R6 are each H.
41. The composition according to claim 40 for wherein Glu is in the form of a pharmaceutically acceptable salt.
42. The composition according to claim 23 wherein R4 is NHR7 and R2, R3, R5 and R6 are each H.
43. The composition according to claim 42 for wherein R7 is α-glutamyl or a pharmaceutically acceptable salt thereof.
44. The composition according to claim 43 wherein R7 is H, α-glutamyl or a pharmaceutically acceptable salt thereof or a polyglutamic acid polypeptide residue or a pharmaceutically acceptable salt thereof.
45. A method of treating non-tumorous cancer in a patient in need of therapy comprising administering to said patient an effective amount of a compound or its pharmaceutically acceptable salt according to the structure:
Where R is —CH3 or —CH2CH2Cl; R′ is C1-C7 alkyl or —CH2CH2Cl;
one of R2 or R4, but not both, is selected from OPO3H2, NO2, OCO(Glu), NHCO(Glu) and NHR7 and the other of R2 or R4 which is unassigned, and R3, R5 and R6, are, independently selected from H, F, Cl, Br, I, OH, OPO3H2, OCH3, CF3, OCF3, NO2, CN, SO2CH3, SO2CF3, COCH3, COOCH3, SCH3, SF5, NHR8, N(R9)2 and C1-C7 alkyl, with the proviso that at least two of R2, R3, R4, R5 and R6 are H; R7 is H, glutamyl or a polyglutamic acid polypeptide residue —COCH(NHR7a)CH2CH2CO2H where R7a is glutamyl or a polyglutamic acid polypeptide residue having from 1 to 50 peptide linkages; R8 is H or C1-C7 alkyl;
and R9 is CH3 or CH2CH3; optionally, in combination with a pharmaceutically acceptable additive, carrier, or excipient.
46. The method according to claim 45 wherein R is —CH2CH2Cl.
47. The method according to claim 45 wherein said R′ is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, n-hexyl, isohexyl or substituted hexyl.
48. The method according to claim 47 wherein R′—CH3.
49. The method according to claim 45 wherein R2 is OPO3H2 or a pharmaceutically acceptable salt thereof.
50. The method according to claim 45 wherein R4 is F, Cl or OCH3 and R3, R5 and R6 are each H.
51. The method according to claim 45 wherein R5 is F, Cl, OCH3 or OCF3 and R3, R4 and R6 are each H.
52. The method according to claim 45 wherein two of R3, R4, R5 or R6 are independently F or Cl.
53. The method according to claim 52 wherein R4 and R5 are independently F or Cl.
54. The method according to claim 52 wherein R5 and R6 are independently F or Cl.
55. The method according to claim 53 wherein R4 and R5 are Cl.
56. The method according to claim 54 wherein R5 and R6 are Cl.
57. The method according to claim 45 wherein R5 is OPO3H2 or a pharmaceutically acceptable salt thereof.
58. The method according to claim 45 wherein R2 is NO2 and R3, R4 and R6 are each H.
59. The method according to claim 45 wherein R4 is NO2 and R2, R3 and R6 are each H.
60. The method according to claim 45 wherein R4 is OCO(Glu) and R2, R3, R5 and R6 are each H.
61. The method according to claim 60 wherein Glu is in the form of a pharmaceutically acceptable salt.
62. The method according to claim 45 wherein R4 is NHCO(Glu) and R2, R3, R5 and R6 are each H.
63. The method according to claim 62 wherein Glu is in the form of a pharmaceutically acceptable salt.
64. The method according to claim 45 wherein R4 is NHR7 and R2, R3, R5 and R6 are each H.
65. The method according to claim 64 wherein R7 is a α-glutamyl or a pharmaceutically acceptable salt thereof.
66. The method according to claim 64 wherein R7 is H, a α-glutamyl or a pharmaceutically acceptable salt thereof or a polyglutamic acid polypeptide residue or a pharmaceutically acceptable salt thereof.
67. The method according to claim 45 wherein said cancer is selected from the group consisting of acute lymphocytic leukemia, acute myelogenous leukemia, or hairy cell leukemia.
68. (Cancelled)
69. A method of treating a drug-resistant non-tumorous cancer in a patient in need thereof, said method comprising administering to said patient an effective amount of a composition according to claims 23 or 24.
70. A method of treating non-tumorous cancer in a patient in need thereof said method comprising administering to said patient an effective amount of a composition according to claims 23 or 24 in combination with at least one additional anti-cancer agent.
71. A method of treating non-tumorous cancer in a patient in need thereof said method comprising administering to said patient an effective amount of a composition according to claims 23 or 24 in combination with at least one additional anti-cancer agent selected from the group consisting of antimetabolites, Ara C, etoposide, doxorubicin, taxol, hydroxyurea, vincristine, cytoxan, mitomycin C, adriamycin, topotecan, campothecin, irinotecan, gemcitabine, and cis-platin.
72. A pharmaceutical composition according to any of claims 23-44 in combination with at least one additional anti-cancer agent.
73. A pharmaceutical composition according to claims 23 or 24 in combination with at least one additional anti-cancer agent selected from the group consisting of antimetabolites, Ara C, etoposide, doxorubicin, taxol, hydroxyurea, vincristine, cytoxan, mitomycin C, adriamycin, topotecan, campothecin, irinotecan, gemcitabine, campothecin and cis-platin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/950,890 US20050043244A1 (en) | 2003-06-13 | 2004-09-27 | Water-soluble SHPs as novel alkylating agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/461,282 US6855695B2 (en) | 2003-06-13 | 2003-06-13 | Water-soluble SHPs as novel alkylating agents |
US10/950,890 US20050043244A1 (en) | 2003-06-13 | 2004-09-27 | Water-soluble SHPs as novel alkylating agents |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/461,282 Division US6855695B2 (en) | 2003-06-13 | 2003-06-13 | Water-soluble SHPs as novel alkylating agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050043244A1 true US20050043244A1 (en) | 2005-02-24 |
Family
ID=33511222
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/461,282 Expired - Lifetime US6855695B2 (en) | 2003-06-13 | 2003-06-13 | Water-soluble SHPs as novel alkylating agents |
US10/950,890 Abandoned US20050043244A1 (en) | 2003-06-13 | 2004-09-27 | Water-soluble SHPs as novel alkylating agents |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/461,282 Expired - Lifetime US6855695B2 (en) | 2003-06-13 | 2003-06-13 | Water-soluble SHPs as novel alkylating agents |
Country Status (7)
Country | Link |
---|---|
US (2) | US6855695B2 (en) |
EP (1) | EP1644025A4 (en) |
JP (1) | JP2007516228A (en) |
CN (1) | CN100427139C (en) |
CA (1) | CA2525091A1 (en) |
HK (1) | HK1089368A1 (en) |
WO (1) | WO2005004897A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258656A1 (en) * | 2003-03-28 | 2006-11-16 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US20080025984A1 (en) * | 2004-03-26 | 2008-01-31 | Ivan King | Combination Therapy Comprising Cloretazine |
US20100183742A1 (en) * | 2006-12-26 | 2010-07-22 | Threshold Pharmaceuticals, Inc | Phosphoramidate alkylator prodrugs for the treatment of cancer |
EP2336141A2 (en) | 2005-06-29 | 2011-06-22 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1793823B1 (en) * | 2004-09-21 | 2012-08-08 | Vion Pharmaceuticals, Inc. | Phosphate containing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents |
CN101321806B (en) * | 2005-12-05 | 2011-01-26 | 日东电工株式会社 | Polyglutamate-amino acid conjugates and methods |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
CN101674852A (en) * | 2007-04-10 | 2010-03-17 | 日东电工株式会社 | Multi-functional polyglutamate drug carriers |
US20080279782A1 (en) * | 2007-05-09 | 2008-11-13 | Nitto Denko Corporation | Polymers conjugated with platinum drugs |
CN101678123B (en) | 2007-05-09 | 2014-07-16 | 日东电工株式会社 | Compositions that include a hydrophobic compound and a polyamino acid conjugate |
US20090118031A1 (en) * | 2007-11-01 | 2009-05-07 | Qualizza Gregory K | Shaft Structure with Configurable Bending Profile |
MX2010009670A (en) * | 2008-03-06 | 2010-09-22 | Nitto Denko Corp | Polymer paclitaxel conjugates and methods for treating cancer. |
CN113121594A (en) * | 2019-01-09 | 2021-07-16 | 西北工业大学 | Phosphoryloxybenzaldehyde oximes or phosphoryloxy benzophenone oximes compound and preparation method thereof |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4175200A (en) * | 1975-04-11 | 1979-11-20 | Uniroyal, Inc. | N,N-Disubstituted sulfonyl hydrazines |
US4385055A (en) * | 1979-01-04 | 1983-05-24 | The United States Of America As Represented By The Secretary Of The Army | 2-Acetyl-and 2-propionylpyridine thiosemicarbazones as antimalarials |
US4447427A (en) * | 1979-01-04 | 1984-05-08 | The United States Of America As Represented By The Secretary Of The Army | Method for treating bacterial infections with 2-acetyl- and 2-propionylpyridine thiosemicarbazones |
US4684747A (en) * | 1984-12-20 | 1987-08-04 | Yale University | N,N'-bis(sulfonyl)hydrazines having antineoplastic activity |
US4696938A (en) * | 1986-04-25 | 1987-09-29 | Rohm And Haas Company | Insecticidal 6-aryl-pyridine thiosemicarbazones |
US4849563A (en) * | 1986-01-21 | 1989-07-18 | Yale University | Novel 1-alkyl-1-arenesulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity |
US5101072A (en) * | 1989-09-06 | 1992-03-31 | Yale University | Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents |
US5214068A (en) * | 1989-09-06 | 1993-05-25 | Yale University | Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents |
US5256820A (en) * | 1991-11-08 | 1993-10-26 | Yale University | 1-alkyl-2-acyl-1,2-disulfonylhydrazines |
US5637619A (en) * | 1995-07-05 | 1997-06-10 | Yale University | Antitumor 2-aminocarbonyl-1, 2-bis(methylsulfonyl)-1-(substituted)hydrazines |
US5767134A (en) * | 1997-05-15 | 1998-06-16 | Vion Pharmaceuticals, Inc. | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
US20030000884A1 (en) * | 1998-10-08 | 2003-01-02 | Hamlin Thomas J. | Composite filter element |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6040338A (en) * | 1997-11-03 | 2000-03-21 | Yale University | N,n-bis(sulfonyl)hydrazines useful as antineoplastic agents |
FR2812633A1 (en) * | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | PHENYL (THIO) UREA AND PHENYL (THIO) CARBAMATE FUNGICIDES DERIVATIVES |
KR20030063360A (en) | 2000-10-13 | 2003-07-28 | 비온 퍼마슈티컬즈 인코포레이티드 | Modified prodrug forms of AP/AMP |
-
2003
- 2003-06-13 US US10/461,282 patent/US6855695B2/en not_active Expired - Lifetime
-
2004
- 2004-05-18 WO PCT/US2004/015547 patent/WO2005004897A1/en active Application Filing
- 2004-05-18 CA CA002525091A patent/CA2525091A1/en not_active Abandoned
- 2004-05-18 CN CNB2004800164701A patent/CN100427139C/en not_active Expired - Fee Related
- 2004-05-18 EP EP04776031A patent/EP1644025A4/en not_active Withdrawn
- 2004-05-18 JP JP2006533183A patent/JP2007516228A/en active Pending
- 2004-09-27 US US10/950,890 patent/US20050043244A1/en not_active Abandoned
-
2006
- 2006-09-04 HK HK06109806A patent/HK1089368A1/en not_active IP Right Cessation
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4175200A (en) * | 1975-04-11 | 1979-11-20 | Uniroyal, Inc. | N,N-Disubstituted sulfonyl hydrazines |
US4385055A (en) * | 1979-01-04 | 1983-05-24 | The United States Of America As Represented By The Secretary Of The Army | 2-Acetyl-and 2-propionylpyridine thiosemicarbazones as antimalarials |
US4447427A (en) * | 1979-01-04 | 1984-05-08 | The United States Of America As Represented By The Secretary Of The Army | Method for treating bacterial infections with 2-acetyl- and 2-propionylpyridine thiosemicarbazones |
US4684747A (en) * | 1984-12-20 | 1987-08-04 | Yale University | N,N'-bis(sulfonyl)hydrazines having antineoplastic activity |
US4849563A (en) * | 1986-01-21 | 1989-07-18 | Yale University | Novel 1-alkyl-1-arenesulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity |
US4696938A (en) * | 1986-04-25 | 1987-09-29 | Rohm And Haas Company | Insecticidal 6-aryl-pyridine thiosemicarbazones |
US5101072A (en) * | 1989-09-06 | 1992-03-31 | Yale University | Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents |
US5214068A (en) * | 1989-09-06 | 1993-05-25 | Yale University | Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents |
US5256820A (en) * | 1991-11-08 | 1993-10-26 | Yale University | 1-alkyl-2-acyl-1,2-disulfonylhydrazines |
US5637619A (en) * | 1995-07-05 | 1997-06-10 | Yale University | Antitumor 2-aminocarbonyl-1, 2-bis(methylsulfonyl)-1-(substituted)hydrazines |
US5767134A (en) * | 1997-05-15 | 1998-06-16 | Vion Pharmaceuticals, Inc. | Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP |
US20030000884A1 (en) * | 1998-10-08 | 2003-01-02 | Hamlin Thomas J. | Composite filter element |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060258656A1 (en) * | 2003-03-28 | 2006-11-16 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US7550496B2 (en) | 2003-03-28 | 2009-06-23 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US20090312276A1 (en) * | 2003-03-28 | 2009-12-17 | Mark Matteucci | Compositions and Methods for Treating Cancer |
US8299088B2 (en) | 2003-03-28 | 2012-10-30 | Threshold Pharmaceuticals, Inc. | Compositions and methods for treating cancer |
US20080025984A1 (en) * | 2004-03-26 | 2008-01-31 | Ivan King | Combination Therapy Comprising Cloretazine |
US7605137B2 (en) | 2004-03-26 | 2009-10-20 | Vion Pharmaceuticals, Inc. | Combination therapy comprising cloretazine |
EP2336141A2 (en) | 2005-06-29 | 2011-06-22 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US8003625B2 (en) | 2005-06-29 | 2011-08-23 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US8507464B2 (en) | 2005-06-29 | 2013-08-13 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US8664204B2 (en) | 2005-06-29 | 2014-03-04 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US9226932B2 (en) | 2005-06-29 | 2016-01-05 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs |
US20100183742A1 (en) * | 2006-12-26 | 2010-07-22 | Threshold Pharmaceuticals, Inc | Phosphoramidate alkylator prodrugs for the treatment of cancer |
US8552048B2 (en) | 2006-12-26 | 2013-10-08 | Threshold Pharmaceuticals, Inc. | Phosphoramidate alkylator prodrugs for the treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
CN100427139C (en) | 2008-10-22 |
JP2007516228A (en) | 2007-06-21 |
EP1644025A4 (en) | 2006-11-15 |
US6855695B2 (en) | 2005-02-15 |
CN1805752A (en) | 2006-07-19 |
EP1644025A1 (en) | 2006-04-12 |
HK1089368A1 (en) | 2006-12-01 |
CA2525091A1 (en) | 2005-01-20 |
US20040254103A1 (en) | 2004-12-16 |
WO2005004897A1 (en) | 2005-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6855695B2 (en) | Water-soluble SHPs as novel alkylating agents | |
US9957250B2 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
JPH09500125A (en) | Prodrugs of protein tyrosine kinase inhibitors | |
US6262053B1 (en) | Melamine derivatives as potent anti-cancer agents | |
EP0717736B1 (en) | Phosphorus derivatives to treat aids | |
US7405317B2 (en) | Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
EP0988285B1 (en) | Prodrug forms of ribonucleotide reductase inhibitors 3-ap and 3-amp | |
CA2423220C (en) | Modified prodrug forms of ap/amp | |
US20200375964A1 (en) | Demethylpenclomedine analogs and their use as anti-cancer agents | |
AU2002211725A1 (en) | Modified prodrug forms of AP/AMP | |
US20210380626A1 (en) | Novel small molecule drug conjugates of gemcitabine derivatives | |
CN114828830A (en) | Pharmaceutical composition and treatment agent | |
CN101022798A (en) | Sulfonyl hydrazines as hypoxia-selective antineoplastic agents | |
MXPA99010422A (en) | Prodrug forms of ribonucleotide reductase inhibitors 3-ap and 3-amp |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |